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“Three things in human life are important: the first is to be kind; the second is to 




“Tenderness and kindness are not signs of weakness and despair, but 




“The true essence of humankind is kindness. There are other qualities which come 
from education or knowledge, but it is essential, if one wishes to be a genuine 
human being and impart satisfying meaning to one’s existence, to have a good 
heart.” 





To my father, a goodhearted man, 
who could not see it and so happy would have made him. 
 
To my son, 
who has inherited his grandfather’s good heart. 
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In high income countries, around 75% of the population will die due to chronic 
conditions. Despite only about one third of those having chronic diseases needing 
palliative care suffer from cancer, palliative care is mainly aimed at patients with 
terminal cancer in institutional settings. Nevertheless, there is strong evidence of 
unmet palliative needs among people with life-threatening non-malignant disease. 
Data in patients with advanced cancer show that early provision of specialty 
palliative care improves quality of life, lowers spending, and helps clarify 
treatment preferences and goals of care. Translating available evidence into health 
systems to deliver early palliative care to all people with advanced chronic 
conditions different than cancer in any setting of care might improve clinical 
outcomes decreasing costs of care in this population. 
Recognising transition 1, the period referred to as end of life preceding terminal 
phase, may enable early palliative care intervention and anticipatory palliative 
care planning. Nevertheless, the right moment to start palliative care -for which 
early identification is a prerequisite- has not been defined yet.  
Acknowledging limitations of available prognostic indices and predictive models, 
with insufficient evidence at this time to recommend their widespread use, a 
pragmatic approach to identify candidates for palliative care advocating a person 
centred approach based not on diagnosis or prognosis, but on their needs has been 
proposed. It is based on asking the surprise question (“Would you be surprised if 
this patient were to die in the next 12 months?”) and looking for one or more 
clinical indicators that would suggest a person might be at risk of deteriorating 
and dying and should be assessed for unmet needs.  
This pragmatic approach is the basis of most of the set of identification indicators 
which have been developed in recent years to recognizing transition 1 and 
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identifying individuals likely in need of palliative care, as the NECPAL CCOMS-
ICO© tool. 
The overall aim of this thesis was to evaluate the usefulness of the NECPAL 
CCOMS-ICO© tool in identifying individuals with advanced chronic conditions 
who may benefit from an early palliative care approach, through employing it as a 
tool to determine the population-based prevalence of these individuals (Study I), 
evaluating its predictive validity for mortality at 3, 6, 12 and 24 months to inform 
usefulness as screening tool for early palliative care (Study II) and identifying the 
indicators that were associated with mortality within 24 months to develop a 
predictive model for identifying individuals at high risk of death (Study III). 
 
Methods 
Study I is a cross-sectional, population-based study. 
Case identification was undertaken in the County of Osona, located north of 
Barcelona, in a) 3 randomly selected primary care centres -i.e. 51595 registered 
inhabitants-, b) all inpatient units of acute bed hospital, c) all inpatient units of 
intermediate care centre, and d) nursing homes, serving these 3 primary care 
centres. Cases were identified by healthcare professionals (physicians and nurses) 
in each health facility. Recruited individuals were assessed by employing the 
NECPAL CCOMS-ICO© tool and categorised as surprise question positive (SQ+) 
when, at least, one of the attending healthcare professionals’ answer was “no” to 
the surprise question. SQ+ individuals were also considered as NECPAL+ when 
they presented, at least, one positive additional indicator from among the 
remaining ones. All individuals classified as NECPAL+ were considered likely in 
need of palliative care.  
Study II is a longitudinal, prospective, cohort study. Individuals from previous 




Study III is a longitudinal, prospective, cohort study. Indicators included in the 
NECPAL CCOMS-ICO© tool and mortality status at 3, 6, 12 and 24 months were 
analysed in the whole cohort of individuals recruited in previous population-based 
prevalence study.  
 
Results 
Study I: A total number of 1063 individuals with advanced chronic conditions 
were recruited. 840 were identified as SQ+, among which 783 were also identified 
as NECPAL+. Population-based prevalence of individuals with advanced chronic 
conditions who may benefit from an early palliative care approach, that is to say 
NECPAL+ individuals, was 1.5%. Almost two thirds were female and the mean 
age was 81 years old. The vast majority were living at home (66.9%) or nursing 
homes (19.6%). The most prevalent conditions among NECPAL+ individuals 
were organ failure (32.3%) and advanced frailty (31.4%), followed by dementia 
(23.4%). Cancer is the less prevalent disease among individuals with advanced 
chronic conditions who may benefit from an early palliative care approach 
(12.9%). 
Study II: A total of 1059 individuals were available for survival analysis. At 12 
months, the NECPAL CCOMS-ICO© tool presents very high sensitivity (91.3, CI: 
87.2-94.2) and very high negative predictive value (NPV) (91.0, CI: 86.9-94.0), 
with low specificity (32.9, CI: 29.6-36.3), explained by high number of false 
positives, and low positive predictive value (PPV) (33.5, CI: 30.2-36.9), explained 
by low number of true positives (low mortality rate) and  high number of false 
positives. At 24 months, it improves specificity (35.0, CI: 31.3-38.7) and PPV 
(45.8, CI: 42.3-49.3), although they remain low, decreasing sensitivity (87.5, CI: 
84.3-90.7) and NPV (81.7, CI: 77.2-86.2).  
Per advanced chronic condition, sensitivity and NPV were similarly high, with 
low specificity. PPV were higher in cancer (64.4, CI: 54.1-73.5 at 12 months; 
71.3, CI: 61.3-79.6 at 24 months), followed by dementia (36.5, CI: 29.5-44.0 at 12 
months; 56.4, CI: 48.8-63.6 at 24 months) and organ failure (30.4, CI: 24.9-36.6 at 
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12 months; 45.8, CI: 42.3-49.3 at 24 months) and, finally, advanced frailty (21.6, 
CI: 16.8-27.4 at 12 months; 30.6, CI: 25.0-36.9 at 24 months). 
Per setting of care, sensitivity and NPV were similarly high, with low specificity. 
PPV is higher in intermediate care centre (67.3, CI: 53.2-79.0 at 12 months; 70.9, 
CI: 56.9-82.0 at 24 months) and acute bed hospital (54.0, CI: 39.5-67.9 at 12 
months; 62.0, CI: 47.2-75.0 at 24 months), followed by nursing homes (33.1, CI: 
25.9-41.2 at 12 months; 57.8, CI: 49.6-65.6 at 24 months) and, finally, primary 
care centres (28.0, CI: 24.2-32.1 at 12 months; 38.0, CI: 33.8-42.3 at 24 months). 
The predictive validity for mortality of the NECPAL CCOMS-ICO© tool and the 
SQ was non-significantly different, neither in the whole population-based sample, 
nor in subgroups by advanced chronic condition and setting of care. 
Study III: The indicators associated with mortality within 24 months among those 
included in the NECPAL CCOMS-ICO© tool vary according to advanced chronic 
condition and setting of care. Two simple predictive models were developed. The 
first one, in advanced frailty; the second one, in organ failure.  
Advanced frailty: In the multivariate Cox model, infections with systemic impact 
(HR 4.11, 95% CI 1.68-10.01), confusional syndrome (HR 2.73, 95% CI 1.71-
4.36), identification of palliative care needs by healthcare professionals (HR 2.70, 
95% CI 1.33-5.52) and complex/intense nursing care needs (HR 2.35, 95% CI 
1.36-4.06) were the indicators included in the NECPAL CCOMS-ICO© tool 
associated with a higher risk of mortality. Some other indicators, as falls (HR 
1.95, 95% CI 1.08-3.50), co-morbidity (Charlson index, HR 1.16, 95% CI 1.05-
1.27), urgent admissions (HR 1.11, 95% CI 1.01-1.23) and age (HR 1.05, 95% CI 
1.02-1.09) were also associated with an increased risk of death within 24 months 
after identification. 
The AUC showed outstanding discrimination at 3 months [0.92 (95% CI 0.85-
0.99)], with highest concurrent sensitivity and specificity above 80%, and 
acceptable discrimination at 6, 12 and 24 months [0.79 (95% CI 0.70-0.87), 0.73 
(95% CI 0.65-0.81) and 0.72 (95% CI 0.66-0.78), respectively]. At 6 and 12 
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months, highest concurrent sensitivity and specificity were above 70%, decreasing 
below this threshold only at 24 months. 
Organ failure: In the multivariate Cox model, the surprise question (HR 3.07, 95% 
CI 1.54-6.15), infections with systemic impact (HR 2.96, 95% CI 1.66-5.26) and 
carer’s request for palliative care approach  (HR 2.31, 95% CI 1.47-3.61) were the 
indicators included in the NECPAL CCOMS-ICO© tool associated with a higher 
risk of mortality. Some other indicators, as falls (HR 1.99, 95% CI 1.03-3.86), 
severe dependency (HR 1.87, 95% CI 1.07-3.27), confusional syndrome (HR 
1.74, 95% CI 1.07-2.83), complex/intense nursing care needs (HR 1.69, 95% CI 
1.08-2.65) and age (HR 1.02, 95% CI 1.003-1.04) were also associated with an 
increased risk of death within 24 months after identification. 
The AUC showed excellent discrimination at 3 months [0.81 (95% CI 0.71-0.91)], 
with highest concurrent sensitivity and specificity around 70%, and acceptable 
discrimination at 6 and 12 months [0.79 (95% CI 0.70-0.88) and 0.74 (95% CI 
0.67-0.81), respectively], with a slightly increase in the AUC at 24 months [0.75 
(95% CI 0.69-0.80). At 6 and 24 months, highest concurrent sensitivity and 
specificity were around 70%. The model’s discrimination ability showed its worse 
AUC, sensitivity and specificity at 12 months. 
 
Conclusions 
The NECPAL CCOMS-ICO© tool can be considered useful in identifying 
individuals with advanced chronic conditions who may benefit from an early 
palliative care approach.  
It can be employed to assess the population-based needs for palliative care 
through identifying prospectively the population-based prevalence of this 
population, an innovative approach which can be potentially useful for improving 
clinical practice. 
It can be used, as well as the SQ, as screening tool for early palliative care. They 
present high sensitivity and high NPV, both important predictive values to 
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identify such a vulnerable and often undetected and under-treated population. 
They can be employed as a first assessment to identify this population, preferably 
accompanied by repeated or additional tests, aiming to improve specificity.  
From a population-based perspective, end of life trajectories may turn out to be an 
excellent conceptual framework for the development of simple predictive models 
to identify individuals at high risk of death, particularly in advanced frailty and 
organ failure, the most prevalent population-based advanced chronic conditions, 
for which simple and promising predictive models have been developed and 




II. Abstract (Catalan version) 
Antecedents 
Als països desenvolupats, al voltant del 75% de la població morirà degut a 
malalties cròniques. Malgrat només un terç dels que tenen malalties cròniques i 
necessiten atenció pal·liativa pateix càncer, les cures pal·liatives estan dirigides 
principalment als pacients amb càncer terminal en entorns institucionals. No 
obstant això , hi ha una forta evidència de les necessitats pal·liatives no satisfetes 
entre les persones amb malaltia no maligna amenaçant per a la vida. 
Les dades en pacients amb càncer avançat mostren que la provisió precoç de cures 
pal·liatives especialitzades milloren la qualitat de vida, disminueix la despesa i 
ajuda a clarificar les preferències de tractament i els objectius d’atenció. 
Traslladar l’evidència disponible als sistemes de salut per oferir atenció pal·liativa 
precoç a totes les persones amb condicions cròniques diferents del càncer a 
qualsevol dispositiu d’atenció podria millorar els resultats clínics disminuint els 
costos d’atenció en aquesta població. 
Reconèixer la primera transició, el període referit com a final de vida, que 
precedeix la fase terminal, podria possibilitar la intervenció pal·liativa precoç i la 
planificació de decisions anticipada. Tot i així, el moment adequat per a començar 
l’atenció pal·liativa -per a la què la identificació precoç és un prerequisit- no ha 
estat definit encara. 
Admetent limitacions d’índex pronòstics i models predictius disponibles, amb 
evidència insuficient actualment per a recomanar el seu ús generalitzat, un 
abordatge pragmàtic per a identificar candidats per a atenció pal·liativa defensant 
un abordatge centrat en la persona basat no en el diagnòstic o el pronòstic, sinó en 
les seves necessitats ha estat proposat. Està basat en preguntar la pregunta 
sorpresa (“El sorprendria que aquest pacient morís en els propers 12 mesos?”) i la 
cerca d’un o més indicadors clínics que podrien suggerir que una persona podria 
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estar en risc de deteriorament i mort i hauria de ser avaluada per a necessitats no 
satisfetes. 
Aquest abordatge pragmàtic és el fonament de la majoria dels sets d’indicadors 
d’identificació que han estat desenvolupats en els últims anys per a reconèixer la 
1a transició i identificar individus amb probable necessitat d’atenció pal·liativa, 
com ara l’instrument NECPAL CCOMS-ICO©. 
L’objectiu general d’aquesta tesi és avaluar la utilitat de l’instrument NECPAL 
CCOMS-ICO© per a identificar individus amb condicions cròniques avançades 
que es podrien beneficiar d’un abordatge pal·liatiu precoç, a través de la seva 
utilització per a determinar la prevalença poblacional d’aquests individus (Estudi 
I), avaluant la seva validesa predictiva per a mortalitat a 3, 6, 12 i 24 mesos per a 
informar la seva utilitat com a instrument de cribratge per a atenció pal·liativa 
precoç (Estudi II) i identificant indicadors associats amb mortalitat en 24 mesos 
per a desenvolupar un model predictiu per a la identificació d’individus en alt risc 
de mort (Estudi III). 
 
Metodologia 
L’estudi I és un estudi poblacional de tall transversal. 
La identificació de casos es va dur a terme a la comarca d’Osona, al nord de 
Barcelona, a a) 3 centres d’atenció primària seleccionats aleatòriament -51595 
habitants registrats-, b) tots els pacients ingressats a l’hospital d’aguts, c) tots els 
pacients ingressats al centre sociosanitari i d) les residències, que servien aquests 
3 centres d’atenció primària. Els casos van ser identificats pels professionals 
sanitaris (metges i infermeres) a cada recurs d’atenció. Els individus reclutats van 
ser avaluats emprant l’instrument NECPAL CCOMS-ICO© i categoritzats com a 
pregunta sorpresa positiu (PS+) quan, almenys, un dels professionals sanitaris va 
respondre “no” a la pregunta sorpresa. Els individus PS+ van ser considerats com 
a NECPAL+ si van presentar, almenys, un indicador positiu addicional de entre 
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els restants. Tots els individus classificats com a NECPAL+ van ser considerats 
com a individus amb probable necessitat d’atenció pal·liativa. 
L’estudi II és un estudi de cohort, prospectiu, longitudinal. Els individus de 
l’estudi previ de prevalença poblacional que van morir al llarg dels 2 anys de 
seguiment de l’estudi van ser identificats. 
L’estudi III és un estudi de cohort, prospectiu, longitudinal. Els indicadors de 
l’instrument NECPAL CCOMS-ICO© i la mortalitat a 3, 6, 12 i 24 mesos van ser 




Estudi I: Un total de 1063 individus amb condicions cròniques avançades van ser 
reclutats. 840 van ser identificats com PS+, entre els que 783 van ser també 
identificats com a NECPAL+. La prevalença poblacional d’individus amb 
condicions cròniques avançades que es podrien beneficiar d’un abordatge 
pal·liatiu precoç, és a dir individus NECPAL+, va ser 1.5%. Quasi dos terços eren 
dones i l’edat mitjana va ser de 81 anys. La gran majoria viuen als seus domicilis 
(66.9%) o a residencies (19.6%). Les condicions més prevalents entre els 
individus NECPAL+ van ser malaltia d’òrgan (32.3%)  i fragilitat avançada 
(31.4%), seguides de demència (23.4%). El càncer és la malaltia menys prevalent 
entre els individus amb condicions cròniques avançades que es podrien beneficiar 
d’un abordatge pal·liatiu (12.9%).  
Estudi II: Un total de 1059 individus van ser seguits per a l’anàlisi de 
supervivència. A 12 mesos, l’instrument NECPAL CCOMS-ICO© presenta una 
molta alta sensibilitat (91.3, IC: 87.2-94.2) i un molt alt valor predictiu negatiu 
(VPN) (91.0, IC: 86.9-94.0), amb baixa especificitat (32.9, IC: 29.6-36.3), 
explicada per l’alt nombre de falsos positius, i baix valor predictiu positiu (VPP) 
(33.5, IC: 30.2-36.9), explicat pel baix nombre de veritables positius (baixa taxa 
de mortalitat) i l’alt nombre de falsos positius. A 24 mesos, millora l’especificitat 
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(35.0, IC: 31.3-38.7) i el VPP (45.8, IC: 42.3-49.3), tot i que continuen sent 
baixos, disminuint la sensibilitat (87.5, IC: 84.3-90.7) i el VPN (81.7, IC: 77.2-
86.2). 
Per condició crònica avançada, la sensibilitat i el VPN van ser igualment alts, amb 
baixa especificitat. El VPP va ser més alt en càncer (64.4, IC: 54.1-73.5 a 12 
mesos; 71.3, IC: 61.3-79.6 a 24 mesos), seguit per demència (36.5, IC: 29.5-44.0 a 
12 mesos; 56.4, IC: 48.8-63.6 a 24 mesos) i malaltia d’òrgan (30.4, IC: 24.9-36.6 
a 12 mesos; 45.8, IC: 42.3-49.3 a 24 mesos) i, finalment, fragilitat avançada (21.6, 
IC: 16.8-27.4 a 12 mesos; 30.6, IC: 25.0-36.9 a 24 mesos). 
Per recurs d’atenció, la sensibilitat i el VPN van ser igualment alts, amb baixa 
especificitat. El VPP va ser més alt al centre sociosanitari (67.3, IC: 53.2-79.0 a 
12 mesos; 70.9, IC: 56.9-82.0 a 24 mesos) i a l’hospital d’aguts (54.0, IC: 39.5-
67.9 a 12 mesos; 62.0, IC: 47.2-75.0 a 24 mesos), seguit de les residències (33.1, 
IC: 25.9-41.2 a 12 mesos; 57.8, IC: 49.6-65.6 a 24 mesos) i, finalment, els centres 
d’atenció primària (28.0, IC: 24.2-32.1 a 12 mesos; 38.0, IC: 33.8-42.3 a 24 
mesos). 
La validesa predictiva per a mortalitat de l’instrument NECPAL CCOMS-ICO© i 
la PS no és significativament diferent, ni a la mostra poblacional ni en els 
subgrups per condició crònica avançada i recurs d’atenció. 
Estudi III: Els indicadors de l’instrument NECPAL CCOMS-ICO©  associats amb 
mortalitat en 24 mesos varien en funció de la condició crònica avançada i segons 
el recurs d’atenció. Dos models predictius simples han estat desenvolupats. El 
primer, en fragilitat avançada; el segon, en malaltia d’òrgan. 
Fragilitat avançada: En el model multivariat de Cox, les infeccions amb afectació 
sistèmica (HR 4.11, 95% IC 1.68-10.01), la síndrome confusional (HR 2.73, 95% 
IC 1.71-4.36), la identificació de necessitats d’atenció pal·liativa per part dels 
professionals sanitaris (HR 2.70, 95% IC 1.33-5.52) i la necessitat de cures 
infermeres complexes/intenses (HR 2.35, 95% IC 1.36-4.06) van ser els 
indicadors de l’instrument NECPAL CCOMS-ICO©  associats amb un risc més alt 
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de mortalitat. Altres indicadors, com les caigudes (HR 1.95, 95% IC 1.08-3.50), la 
comorbiditat (índex de Charlson, HR 1.16, 95% IC 1.05-1.27), els ingressos 
urgents (HR 1.11, 95% IC 1.01-1.23) i l’edat (HR 1.05, 95% IC 1.02-1.09) estan 
associats també amb un risc augmentat de mort en 24 mesos després de la 
identificació. 
L’AUC va mostrar una discriminació excel·lent a 3 mesos [0.92 (95% IC 0.85-
0.99)], amb la major sensibilitat i especificitat concurrent per sobre del 80%, i una 
discriminació acceptable a 6, 12 i 24 mesos [0.79 (95% IC 0.70-0.87), 0.73 (95% 
IC 0.65-0.81) i 0.72 (95% IC 0.66-0.78), respectivament]. A 6 i 12 mesos, la 
major sensibilitat i especificitat concurrent va ser superior al 70%, disminuint per 
sota d’aquest llindar només a 24 mesos. 
Malaltia d’òrgan: En el model multivariat de Cox,, la pregunta sorpresa (HR 3.07, 
95% IC 1.54-6.15), les infeccions amb afectació sistèmica (HR 2.96, 95% IC 
1.66-5.26) i la demanda del cuidador d’un abordatge pal·liatiu  (HR 2.31, 95% IC 
1.47-3.61) van ser els indicadors de l’instrument NECPAL CCOMS-ICO©  
associats amb un risc més alt de mortalitat. Altres indicadors, como les caigudes 
(HR 1.99, 95% IC 1.03-3.86), la dependència severa (HR 1.87, 95% IC 1.07-
3.27), la síndrome confusional (HR 1.74, 95% IC 1.07-2.83), la necessitat de cures 
infermeres complexes/intenses (HR 1.69, 95% IC 1.08-2.65) i l’edat (HR 1.02, 
95% IC 1.003-1.04) estan associats també amb un risc augmentat de mort en 24 
mesos després de la identificació. 
L’AUC va mostrar una discriminació molt bona a 3 mesos [0.81 (95% CI 0.71-
0.91)], amb la major sensibilitat i especificitat concurrent al voltant del 70%, i una 
discriminació acceptable a 6 i 12 mesos [0.79 (95% CI 0.70-0.88) i 0.74 (95% CI 
0.67-0.81), respectivament], amb un discret augment de l’AUC a 24 mesos [0.75 
(95% CI 0.69-0.80). A 6 i 24 mesos, la major sensibilitat i especificitat concurrent 
va estar al voltant del 70%. L’habilitat de discriminació del model va mostrar la 





L’instrument NECPAL CCOMS-ICO©  pot ser considerat útil per a identificar 
individus amb condicions cròniques avançades que es podrien beneficiar d’un 
abordatge pal·liatiu precoç. 
Pot ser utilitzat per a avaluar les necessitats poblacionals d’atenció pal·liativa a 
través de la identificació prospectiva de la prevalença poblacional d’aquesta 
població, un abordatge innovador que, potencialment, pot ser útil per a millorar la 
pràctica clínica. 
Pot ser utilitzat, de la mateixa manera que la PS, com a instrument de cribratge per 
a atenció pal·liativa precoç. Presenten alta sensibilitat i alt VPN, tots dos valors 
predictius importants per a identificar a aquesta vulnerable població, freqüentment 
no detectada i infratractada. Poden ser utilitzats com a primera mesura per a 
identificar aquesta població, preferentment acompanyat d’exploracions repetides o 
addicionals, per tal de millorar-ne l’especificitat. 
Des d’una perspectiva poblacional, les trajectòries de final de vida podrien 
resultar ser un excel·lent marc conceptual per al desenvolupament de models 
predictius simples per a la identificació de persones en risc alt de mort, 
particularment en fragilitat avançada i malaltia d’òrgan, les condicions cròniques 
avançades poblacionals més prevalents, per a les què s’han desenvolupat models 
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Unmet need for palliative care 
Worldwide, it is estimated that more than 20 million people need palliative care at 
the end of life each year. Only about 14% of people in need of palliative care 
currently receive it, approximately 3 million people, mostly in high-income 
countries. 78% of the unmet need for palliative care is in low-income and middle-
income countries.1 
It has been recently reported that only 20 countries worldwide -of 234 countries, 
territories and areas studied- have palliative care well integrated into their health-
care systems (Australia, Austria, Belgium, Canada, France, Germany, Hong Kong 
Special Administrative Region, Iceland, Ireland, Italy, Japan, Norway, Poland, 
Romania, Singapore, Sweden, Switzerland, Uganda, United Kingdom and United 
States of America), 42% have no palliative care services at all and a further 32% 
have only isolated palliative care services.2 
The number of people requiring palliative care rises to at least 40 million if all 
those that could benefit from palliative care at an earlier stage of their illness are 
included. This number increases at least double if support to family members is 
also encompassed.3 
Palliative care is required for a wide range of diseases. The majority of adults in 
need of palliative care have chronic diseases such as cardiovascular diseases 
(39%), cancer (34%), chronic respiratory diseases (10%) and AIDS (6%), among 
other life-threatening diseases as kidney failure, chronic liver disease, 
neurological disease or dementia.3 4 
Despite only about one third of those having chronic diseases needing palliative 
care suffer from cancer, in most countries, palliative care is mainly aimed at 
patients with terminal cancer in institutional settings.5  Hospice is underutilized 
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for patients with non-malignant yet life-threatening diseases6 7 and they are under-
registered in primary care for palliative care before they die.8  Nevertheless, there 
is strong evidence of unmet need for symptom control, psychosocial and family 
support, informed and open communication and choice at end of life among 
people with life-threatening non-malignant disease.9 10 11 12 
It is foreseen an increased need for palliative care with increasing ageing 
populations and the inexorable rise of chronic diseases worldwide,13 with their 
attendant burden of need, demands of care, and use of resources.14 15 16 17 
 
Strengthening of palliative care as a component of comprehensive care 
throughout the life course  
In order to satisfy this unmet need for palliative care worldwide, the first ever 
global resolution on palliative care was launched by the World Health Assembly 
in 2014.18 
Palliative care has been defined as an approach that improves the quality of life of 
patients (adults and children) and their families who are facing the problems 
associated with life-threatening illness, through the prevention and relief of 
suffering by means of early identification and correct assessment and treatment of 
pain and other problems, whether physical, psychosocial or spiritual. It has been 
acknowledged that alleviation of suffering is an ethical responsibility of health 
systems and an ethical duty of health care professionals. 
Palliative care, when indicated, is considered to be fundamental to improving the 
quality of life, well-being, comfort and human dignity for individuals. Inadequate 
integration of palliative care into health and social care systems is considered to 
be a major contributing factor to the lack of equitable access to such care.  
WHO and Members States have been urged to develop, strengthen and 
implement, where appropriate, palliative care policies to support the 
comprehensive strengthening of health systems to integrate evidence-based, cost-
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effective and equitable palliative care services in the continuum of care, across all 
levels, with emphasis on primary care, community and home-based care, and 
universal coverage schemes. 
 
End of life, end of life transitions and early palliative care 
There is a lack of clear definition for several concepts regarding end of life care, 
which include, among others terns, “end of life” itself (different survival durations 
are considered for this period, ranging from less than 24 months to days) and 
“transition of care”.19 
Despite de paucity of references in the literature aimed at conceptualizing or 
defining “end of life” and “transition of care”, a preliminary conceptual 
framework to help build standardized consensual definitions have been recently 
developed (Figure 1). End of life, sharing similar meaning with terminally ill and 
terminal care, has been defined as progressive life-limiting disease with a 
prognosis of months or less. Transition of care has been defined as evolving place, 
level and goals of care.20 
 
Figure 1. A conceptual framework toward understanding “actively dying”, “end of life”, “terminally 





In recent years, two different end of life transitions have been proposed21 (Figure 
2): a) transition 1, recognising the period referred to as end of life; and b) 
transition 2, recognising the period, days or some week, preceding imminent 
death. 
 
Figure 2. Key phases in end of life care. Boyd K et al. BMJ 2010;341:c4863 
 
 
Despite there is an urgent need to develop consensus definitions for terms 
regarding end of life care, palliative care delivered in period after recognition of 
transition 1 might be identified as early palliative care whereas palliative care 
delivered in period after recognition of transition 2 might be identified as 
traditional palliative care. 22 23 
 
Effectiveness of early palliative care 
Palliative care may be most effective when considered early in the course of the 
illness. Studies in patients with advanced cancer show that early provision of 
specialty palliative care improves quality of life, lowers spending, and helps 
clarify treatment preferences and goals of care. Patients who access earlier 
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specialty palliative care have better clinical outcomes at potentially lower costs.24 
25 26 27 28 
Although death is not necessarily a high cost event in itself, analysis has shown 
the last year of life to be characterised by high healthcare costs and therefore of 
great significance to health providers and insurers.29 
Translating available evidence into health systems to deliver early palliative care 
to all people with advanced chronic conditions different than cancer in any setting 
of care might improve clinical outcomes decreasing costs of care in this 
population. 22 30 31 32 33 
 
 
End of life trajectories and early palliative care 
Trajectories of functional decline at the end of life are quite variable and has been 
determined to differ among 3 types of illness trajectories (Figure 3): a) cancer 
death: with steady progression, where advanced incurable illness can, in general, 
be identified and, usually, a clear terminal phase, allowing performance of 
activities of daily living until quite late; b) death from organ failure: with gradual 
decline, punctuated by episodes of acute deterioration and some recovery, with 
more sudden, seemingly unexpected death, which takes place when the severity of 
the exacerbation and the patient’s dwindling reserves eventually intersect; and c) 
dementia/frailty: with prolonged functional dwindling and gradual decline, being 
needed long-term help with the activities of daily living.34 35 36 Nevertheless, these 
models have not been confirmed by research and recent findings do question the 
existence of a predictable pattern of disability in the last year of life based on the 




Figure. 3. Typical illness trajectories for people with progressive chronic illness. Adapted from Lynn 
and Adamson (Lynn J, Adamson DM: Living well at the end of life. Adapting health care to serious 






Identification of people with advanced chronic conditions when they are starting 
to need a change in place, levels and goals of care, that is recognising transition 1 
whatever which end of life trajectory is followed, may have important 
implications for the organization and delivery of care at the end of life, enabling 
early palliative care intervention and anticipatory palliative care planning. 
Nevertheless, for none of these trajectories the right moment to start palliative 
care -for which early identification is a prerequisite- has been defined yet, 
particularly regarding patients with non-malignant diseases (Figure 4).38 It has not 
been identified any validated tool that could predict the optimal timing to initiate 




Figure 4. What is the moment to start palliative care? A modified figure of Lynn and Adamson 
(Lynn J, Adamson DM: Living well at the end of life. Adapting health care to serious chronic illness 
in old age. Washington: RAND health; 2003) Thoonsen B et al. BMC Family Practice 2011, 12:123 
 
 
Prognostication in advanced chronic conditions 
Prognostication -the process of addressing “what to expect” for an individual's 
disease course- is essential for meaningful decision-making and end of life 
planning in advanced illness.40 The goal of estimating prognosis is to improve 
clinical decision making and, ultimately, patient outcomes. Clinical decisions are 
not fully informed unless the patient’s prognosis is considered.41  
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However, prognostication is a greater challenge in non-malignant disease.42 
Compared with cancer, which shows a pattern of decline monophasic and easier to 
anticipate, determining prognosis is more complicated in life-threatening non-
malignant disease. Most of these diseases have ‘entry–re-entry’ death trajectories, 
involving episodic, acute exacerbations, frequent hospitalisation, stabilisation and 
steady decline, making determination of palliative status and referral to palliative 
care more problematic.43 44 
 
Clinician’s temporal prediction is not a very reliable or robust method of 
predicting survival. Clinicians’ estimates, even in cancer patients, are inaccurate, 
over-optimistic and affected by factors such as training, experience, seniority, and 
level of acquaintance with the patient.45 46 Prediction rules have been shown to 
outperform clinicians in terms of prognostication,47 48 whereas human prediction 
on its own is fraught with bias.49 Consequently, clinicians may find prognostic 
models that attempt to estimate survival useful to help inform their clinical 
judgment. 
 
Specific tools have been developed to aid clinicians estimate survival in both 
cancer patients50 51 52 and non-cancer patients and, among these, from perspectives 
of disease-specific prognostic models53 54 55 and generic prognostic models.56 57 
 
Prognostic models that have attempted to estimate survival of ≤6 months in non-
cancer patients have shown generally poor discrimination, reflecting the less 
predictable nature of most non-malignant disease.58 
 
A systematic review to describe the quality and limitations of validated non–
disease-specific prognostic indices that predict absolute risk of all-cause mortality 
in older adults has been recently performed.59 Perspective of disease-specific 
prognostic models is refused, arguing that older adults are more likely to have 
more than one chronic illness, as multimorbidity becomes progressively more 
common with age,60 61 62 challenging the single-disease framework by which most 
health care, and medical research and education is configured.14 Several validated 
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non-disease-specific prognostic indices for predicting overall mortality -from 6 
months to 5 years- for older adults in different clinical settings  -community,63 64 65 
66 67 68 nursing home69 70 and hospital-71 72 73 74 75 76 57 77 have been identified. 
Nevertheless, concerns regarding their quality -validation by investigators not 
involved in studies’ development (only 2 indices), prospective validation in large 
diverse sample (none), presentation of confidence intervals for either measures of 
discrimination and calibration (only 2 indices), presence of potential sources of 
bias (all) and test of transportability (limited)- and limitations -requirement of 
information that may not be routinely assessed in elderly patients or relying on 
clinical information from administrative data set (insufficiently accurate), not 
suited to clinical use and the current existence of updated versions, with changed 
or no longer present variables, since the development of indices- have been 
pointed out.  
 
The indices’ ability to better target interventions and improve clinical outcomes, 
the ultimate goal of estimating prognosis, has not been proved yet. Research into 
diagnostic tests is scant. Awareness of the need for evidence based diagnostic 
testing must be increased as valid evidence is necessary before introducing a 
diagnostic test in clinical practice.78 This evidence should come from large 
prospective trials that randomize clinicians to using the index or not, evaluating 
the effect of the index on prognostic estimates, clinical decision making and 
patient outcomes. Such large randomized trials have not been performed. 
Therefore, there is insufficient evidence at this time to recommend the widespread 
use of prognostic indices in clinical practice59 and, consequently, an alternative 
approach to those based on prognostic tools to identify people approaching end of 
life is needed. 
 
 
Pragmatic approach to identify people nearing end of life 
End of life care and palliative care might not be bounded by a specific prognosis; 
rather, it might involve the recognition of the irreversibility of a life-limiting 
medical condition that will likely result in death.79 
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Specialist palliative care is one component of palliative care service delivery and 
should be available to people in any care setting who need additional expertise, as 
a resource to support ongoing care by other clinical teams.80 30 31 To optimise 
quality of life for patients with life-threatening disease, palliative care should run 
in parallel with potentially curative or disease-modifying treatment.81 82 
But, in view of the unmet need for palliative care and the increasing numbers of 
people who could benefit, a sustainable, quality and accessible palliative care 
system should be integrated into primary health care, community and home-based 
care, and hospital care, encompassing a public health approach.18 3 
Acknowledging limitations of prognostic indices and predictive models, a 
pragmatic approach to identify candidates for palliative care needs assessment in 
primary and secondary care, advocating a person centred approach based not on 
diagnosis or prognosis, but on the needs of patients and carers in all settings of 
care -home, care home, and hospital- has been proposed.21 This pragmatic 
approach underpins the end of life care strategies that have been implemented in 
some countries to improving end of life care delivered by primary care teams, 
hospital staff, and social care services.83 84 85 
According to this pragmatic approach, recognising transition 2, that is to say, 
identifying patients who are likely to die within days or some week, the period 
preceding imminent death, might be done using indicators for terminal care based 
on clinical judgement after careful assessment in all care settings. Recognising 
transition 2 is considered a core clinical skill, as some core elements of palliative 
care should be routine aspects of care delivered by any healthcare professional.30 
Recognising transition 1 by healthcare professional in both primary and secondary 
care, that is to say, identifying patients who are likely approaching end of life, 
might be done a) asking themselves what has come to be called as the “surprise 
question”, updated from its initial version:81 “Would you be surprised if this 
patient were to die in the next 12 months?”. If the answer is no, then b) using 
readily identifiable prognostic indicators based on the clinical features of different 
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advanced illnesses,34 86 87 updated and complemented with those that have been 
proved to be reliable indicators of end of life situation,88 and clinical judgment.  
 
This pragmatic approach for recognising transition 1, based on asking the surprise 
question and looking for one or more clinical indicators that would suggest a 
person might be at risk of deteriorating and dying and should be assessed for 
unmet needs, is the basis of most of the set of identification indicators, conceived 
as a tools or structured methods, which have been developed in recent years to 
identifying individuals with palliative care needs,89 as the Prognostic Indicator 
Guidance (PIG) of the UK-based Gold Standard Framework (GSF)90, the 
Supportive and Palliative Care Indicators Tool (SPICT) in Scotland,21 the 
Radboud indicators for Palliative Care needs (RADPAC) in the Netherlands,91 and 
the NECPAL CCOMS-ICO© tool in Catalonia, Spain,92 among others. 93 94 95  
 
All these tools have been developed to be used in primary care; however, SPICT, 
PIG and NECPAL CCOMS-ICO© tools are currently also being used in hospital 
settings and nursing homes.96 97 98 99 89 
 
It has been generally assumed that individuals which have been positively 
identified using any of these available tools do have indeed palliative care needs. 
It is important to point out that this conclusion cannot be reached directly, as their 
predictive validity for unmet palliative care needs has not been evaluated yet.89 
Thus, expressions as “individuals likely in need of palliative care” or “individuals 




The NECPAL CCOMS-ICO© tool 
A comprehensive palliative care programme has been implemented in Catalonia 
since 1990.100 Last efficacy assessment performed identified a) considerable 
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variation in uptake of care facilities by patients with advanced life-threatening 
non-malignant diseases; b) a need to embed a palliative care approach into 
conventional services in all settings of the National Health Service (NHS), 
especially in the community; and c) substantial variation of coverage and models 
between districts.101 
To address these challenges, a comprehensive programme has been designed and 
implemented jointly by the WHO Collaborating Centre for Public Health 
Palliative Care Programs and the Catalan Department of Health.102 85 It is in this 
context, and as a first measure, that the NECPAL CCOMS-ICO© tool was 
developed. 
The NECPAL CCOMS-ICO© tool is derived from the PIG combined with a 
further literature review and expert consensus. It has been content-validated in the 
clinical and cultural contexts of Spain and Catalonia.92  
Most prognostic and screening tools for people with advanced chronic conditions 
who may benefit from a palliative care approach have been progressively 
incorporating general indicators from different domains (functional, nutritional 
and cognitive status; emotional problems, geriatric syndromes, social vulnerability 
and others) with solid death predictive values that have been proven to be reliable 
indicators of end of life situation.88 
Compared with similar existing tools,90 21 91 93 94 95 the NECPAL CCOMS-ICO© 
tool (Figures 5-8) is strengthened by containing psychological domain, geriatric 
syndromes, and any progression of functional and nutritional decline as prognostic 
indicators. Furthermore, geriatric syndromes and concepts of severity and 
progression in clinical assessment of tool’s indicators are considered determinant 
domains in identifying advanced severe frailty, contemplated in the NECPAL 
CCOMS-ICO© tool as a general and transversal predictor of mortality. 
Additionally, it is also the only such tool which integrated the request of the 
patient or family for palliative approach, that is to say patient or carer expressed 










 Figure 6. The NECPAL CCOMS-ICO© tool (clinical version). Category 2: choice/request or need 
for palliative care approach. 
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Figure 7. The NECPAL CCOMS-ICO© tool (clinical version). Category 3: general clinical 







 Figure 8. The NECPAL CCOMS-ICO© tool (clinical version). Category 4: disease-specific 




Population-based needs assessment for palliative care 
In high income countries, around 75% of the population will die due to chronic 
conditions, with the ratio of cancer to non-cancer of about 1:2.103  
The first step in delivering appropriate palliative care is to identify prospectively 
those individuals within a given population who require such care, becoming 
essential in generating public health oriented palliative care planning. To date, 
population-based needs assessment for palliative care has been retrospectively 
estimated by examining cause of death data or employing estimations. 104 105 106 107 
108 109 110 111 
Although the available tools to identify individuals who may benefit from an early 
palliative care approach90 21 91 92 93 94 95 have been developed with the aim to 
identify those individuals who may require such care, to the best of our 
knowledge none of them have been employed as a tool to assess the population-
based needs for palliative care through identifying the population-based 
prevalence of these individuals (Study I). 
 
Predictive validity 
A person centred approach based not on diagnosis or prognosis, but on the needs 
of patients and carers in all care settings underpins pragmatic approach for 
identifying individuals who may benefit from an early palliative care 
intervention.21 Nevertheless, prognosis plays a central role in clinical decision 
making.41 With ready access to critical prognostic information, healthcare 
professionals will be better equipped to make clinical decisions that are aligned 
with their patients’ values, preferences, and goals of care.112 Moreover, patients 
say that understanding prognosis is important for making life choices, such as 
engaging in financial planning, arranging custodial care, and deciding when it’s 
important for long-distance family members to visit.113 Palliative needs and 
prognosis are both core aspects of end of life care. 
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The predictive validity for mortality of available tools to identify individuals who 
may benefit from an early palliative care approach has received scant attention, in 
large part because the primary aim of these tools is not to predict mortality, but 
rather to identify patients with unmet palliative care needs. Although these tools 
have good face validity, none of them have been validated neither to predict 
unmet palliative care needs nor to predict mortality. There are insufficient data on 
their sensitivity, specificity and predictive values with a need for evidence to 
inform their usefulness.89 
Although the available tools to identify individuals who may benefit from an early 
palliative care approach90 21 91 92 93 94 95 have been developed with the aim to 
identify those individuals who may require such care, to the best of our 
knowledge none of them have been evaluated to determine its predictive validity 
for mortality to inform their usefulness as screening tool for early palliative care 
from a population-based perspective (Study II). 
 
Predictive models 
In the 21st century, much of clinical practice involves caring for patients with 
advanced, progressive, life limiting illness. Prognosis needs to be restored as a 
core clinical skill, to optimize the patient’s treatment and planning.114 
A key challenge now facing health and social services is how to identify 
individuals who are at high risk of death and for whom, according to available 
evidence, an early palliative care intervention might reduce suffering and improve 
quality of life.24 25 26 27 28 ‘Case-finding’ is the term given to the practice of 
identifying at-risk patients.115 
In order for early palliative care intervention to have an impact on health 
outcomes of people with advanced chronic conditions and, subsequently, on their 
quality of life and dying, it would be convenient, as a first step, an effective and 
accurate system of case-finding were developed, with the specific aim of 
identifying those at risk of death. Simple, well-validated predictive models that 
32 
 
provide clinicians with objective measures of palliative status in patients with 
advanced chronic conditions are needed.58 39 59 
Although the available tools to identify individuals who may benefit from an early 
palliative care approach90 21 91 92 93 94 95 have been developed with the aim to 
identify those individuals who may require such care, using readily identifiable 
generic and disease-specific prognostic indicators which have been proven to be 
reliable indicators of end of life situation, to the best of our knowledge none of 
them have been employed to develop an effective and simple predictive model for 




V. Research aims 
I. Study I 
The primary aim of this study was to determine the population-based prevalence 
of individuals with advanced chronic conditions who may benefit from an early 
palliative care approach identified by the NECPAL CCOMS-ICO© tool in a mixed 
urban-rural district in the north of Barcelona. Additionally, the prevalence was 
determined per setting of care. The secondary aim was to evaluate the degree of 
agreement between physicians and nurses in identifying individuals. The tertiary 
aim was to describe characteristics of identified individuals, according to 
indicators included in the NECPAL CCOMS-ICO© tool, advanced chronic 
condition and setting of care.  
 
 
II. Study II 
The primary aim of this study was to evaluate the predictive validity for mortality 
at 3, 6, 12 and 24 months of the NECPAL CCOMS-ICO© tool to inform 
usefulness as screening tool for early palliative care in individuals with advanced 
chronic conditions identified in a mixed urban-rural district in the north of 
Barcelona. The secondary aim was to evaluate the predictive validity for 
mortality, in the same time points, of the SQ. The tertiary aim was to compare 
mortality rates between NECPAL and Surprise Question identification (positive 
vs negative).  Additionally, primary, secondary and tertiary aims were explored 





III. Study III 
The primary aim of this study was to identify factors that are associated with 
mortality within 24 months using the indicators included in the NECPAL 
CCOMS-ICO© tool in individuals with advanced chronic conditions identified in a 
mixed urban-rural district in the north of Barcelona. The secondary aim was to 
develop a predictive model for identifying individuals at high risk of death. 
Additionally, primary and secondary aims were explored per advanced chronic 






The County of Osona is 1260 sq. km in areal extent, located north of Barcelona in 
the Autonomous Region of Catalonia (Spain). It is a mixed urban-rural district 
with a total population of 156807 inhabitants, 21.4% of whom are >65 years of 
age. The annual mortality rate is 8.81 per 1000.  
It has a complete range of health and social care resources including 11 primary 
care centres; 1 acute bed hospital of 210 beds; 2 intermediate care centres, which 
provide rehabilitation, palliative care, long-term care, and dementia facilities; and 
22 nursing homes, with a total of 1178 beds. It also has a comprehensive 
organisational system for geriatric, dementia, palliative and chronic care across all 
settings formally coordinated and linked by a common computerised information 
system. Care is publicly funded within the NHS and is free at the point of access. 
All inhabitants are registered to one of the primary care centres.   
The primary care centres of the County were classified as urban, rural–urban and 
rural areas. Once stratified, one primary care centre from each stratum was 
randomly selected by using a lottery system, and invited to participate. Primary 
care centres selected were, respectively, Vic-Sud (23985 inhabitants), Santa 
Eugènia de Berga (17529 inhabitants), and Roda de Ter (10081 inhabitants), i.e. 
51595 registered inhabitants (32.9% of the County’s total population). The rest of 
settings included in the study were the acute bed hospital of the county (Hospital 
General de Vic), 4 nursing homes (El Nadal, Vilademany, Can Planolas and 
L’Esquirol) and 1 intermediate care centre (Hospital de la Santa Creu) serving 
these primary care centres. All invited settings agreed to participate. 
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 Figure 9. Centres participating in the study. 
 
Case identification was undertaken in the period of November 2010 to October 
2011 in a) selected primary care centres, b) all inpatient units of acute bed 
hospital, c) all inpatient units of intermediate care centre, and d) nursing homes, 
serving these 3 primary care centres.  
We excluded outpatient clinics, adult day care facilities and day hospitals on the 
assumption that these patients would be identified by their healthcare 
professionals in primary care centres. Patients admitted to acute bed hospital and 
intermediate care centre but living in areas served by other primary care centres 
not included in the study were also excluded, as well as residents in nursing 
homes living there for less than 1 year and place of residence served by other 
primary care centres. 
Cases were identified by healthcare professionals (physicians and nurses) in each 
health facility. In primary care centres, a list of patients suffering from advanced 
chronic conditions was generated using different methods, including primary care 
clinical risk groups (CRGs),116 117 home care users and registers, if available, of 
patients with any of the 10 selected chronic diseases or conditions identified as 











Can Planolas (Roda de Ter)












Figure 10. Diseases and conditions included in the NECPAL CCOMS-ICO© tool, identifying to 
whom should be administered (inclusion criteria). 
 
 
In inpatient settings, case identification was made from lists of admitted patients. 
From these lists, physician and nurse were asked to select (individually and, 
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afterwards, in combination) all possible individuals with advanced chronic 
conditions to elaborate the final list (cohort recruited). Agreement between 
physician and nurse was not mandatory for recruitment. 
 
 Ethical oversight 
This research project was formally approved by the ethical research committees of 
institutions involved in its execution (2010/PREVOsona: P10/65 and EO65) and 
patient informed consent was not required on the basis of the routine nature, 
without specific study-assessments or procedures, of information collected from 




I. Study I 
Study Design 
This is a cross-sectional, population-based study to determine the population-
based prevalence of individuals with advanced chronic conditions and palliative 




To determine the population-based prevalence of patients with advanced chronic 
conditions in need of a palliative care approach, it was employed the Catalan 
version of the NECPAL CCOMS-ICO© tool,118 which has the following categories 
and indicators (study variables): 
Ø Category 1: THE SURPRISE QUESTION 
• Would you be surprised if this patient were to die in the next 12 months? 
 
Ø Category 2: CHOICE / REQUEST OR NEED  
• Choice / Request: Have either the patient with advanced disease or the 
main caregiver requested, in explicit or implicit manner, 
palliative/comfort treatments exclusively? Do they suggest limitation of 
therapeutic effort or reject specific treatments or those with curative 
purposes?  
• Need:  Do you consider this patient requires palliative care or palliative 
treatment at this moment?  
 




a) Nutritional markers, any of the following, in the last 6 months:  
• Clinical perception of nutritional decline (sustained, intense/severe, 
progressive, irreversible) not related to     concurrent conditions  
• Severity: serum albumin < 2.5 g/dl, not related to acute episodes of 
decompensation 
• Progression: weight loss > 10% 
 
b) Functional markers, any of the following, in the last 6 months: 
• Clinical perception of functional decline (sustained, intense/severe, 
progressive, irreversible) not related to concurrent conditions 
• Severity: serious established functional dependence (Barthel score< 20, 
ECOG >2, Karnosky score <50%) 
• Progression: loss of 2 or more activities of daily living (ADL’s) even 
though there is adequate therapeutic intervention 
 
c) Other markers of severity and extreme frailty, at least 2 of the following, in 
the last 6 months: 
• Persistent pressure ulcers (stage III – IV) 
• Recurrent infections (> 1) 
• Delirium  
• Persistent dysphagia  
• Falls (> 2)  
 
d) Presence of emotional distress with psychological symptoms (sustained, 
intense/severe, progressive) not related to acute concurrent conditions  
 
e) Additional factors on use of resources. Any of the following:  
• urgent (unplanned) hospital (or skilled nursing facilities) admissions due 
to chronic disease in last year  
• Need of complex/intensive continuing nursing care, either at an institution 
or at home  
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f) Co-morbidity: Charlson index 
 
Ø Category 4: SPECIFIC CLINICAL INDICATORS OF SEVERITY & 
PROGRESSION PER DISEASES  
a) CANCER (it requires the presence of one single criterion): 
• Patients with confirmed diagnosis of metastatic cancer (stage IV; and also 
stage III in some cases –e.g. lung, pancreas, stomach and oesophagus 
cancers) who present low response or contraindication of specific 
treatment, progressive outbreak during treatment or metastatic affectation 
of vital organs (CNS, liver, severe pulmonary disease, etc.) 
• Significant functional deteriorating (Palliative Performance Status (PPS) 
< 50%)  
• Persistent, troublesome symptoms, despite optimal treatment of 
underlying conditions 
 
b) CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) (presence of 
two or more of the following criteria): 
• Breathlessness at rest or on minimal exertion between exacerbations 
• Difficult physical or psychological symptoms despite optimal tolerated 
therapy 
• In case of having functional respiratory tests (with caveats about quality 
of testing), disease assessed to be severe: FEV1 <30% or     criteria of 
restricted severe deficit: CVF < 40% / DLCO < 40% 
• In case of having arterial blood gases (ABG), accomplishment of oxygen 
therapy at home criteria or such treatment underway 
• Symptomatic heart failure 
• Recurrent hospital admissions (> 3 admissions in 12 months due to 
exacerbations of EPOC)  
 




• Heart failure NYHA stage III or IV, severe valve disease or inoperable 
coronary artery disease  
• Shortness of breath at rest or minimal exertion 
• Difficult physical or psychological symptoms despite optimal tolerated 
• In case of having echocardiography: ejection fraction severely affected (< 
30%) or severe pulmonary hypertension (Pulmonary pressure > 60 
mmHg) 
• Renal failure (FG < 30 l/min) 
• Repeated hospital admissions with symptoms of heart failure /ischemic 
heart disease (> 3 last year)  
 
d) CHRONIC NEUROLOGICAL DISEASES (1): CVA (it requires the presence 
of one single criterion): 
• During acute and sub-acute phases (< 3 months post-stroke): persistent 
vegetative or minimal conscious state > 3 days 
• During the chronic phase (> 3 months post-stroke): repeated medical 
complications (aspiration pneumonia despite dysphagia prevention), 
pyelonephritis (>1), recurrent febrile episodes a despite antibiotics 
(persistent temperature post > 1 week of antibiotics), pressure ulcers stage 
3-4 or dementia with severe criteria post-stroke  
 
e) CHRONIC NEUROLOGICAL DISEASES (2): ALS & MOTOR NEURONE 
DISEASES, MÚLTIPLE SCLEROSIS & PARKINSON (presence of two or 
more of the following criteria):  
• Progressive deterioration in physical and/or cognitive function despite 
optimal therapy 
• Complex and difficult symptoms 
• Speech problems with increasing difficulty communicating 
• Progressive dysphagia  
• Recurrent aspiration pneumonia, breathless or respiratory failure  
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f) SERIOUS CHRONIC LIVER DISEASE (it requires the presence of one 
single criterion): 
• Advanced cirrhosis: stage Child C (determined in lack of complications or 
having treated them and optimized the treatment), MELD-Na score > 30 
or with one or more of the following medical complications: diuretic 
resistant ascites, hepatorenal syndrome or upper gastrointestinal bleeding 
due to portal hypertension with failed response to pharmacologic and 
endoscopic treatment and with contraindicated transplant and TIPS 
• Hepatocellular carcinoma: present, in stage C or D (BCLC) 
 
g) SERIOUS CHRONIC RENAL DISEASE (it requires the presence of one 
single criterion): 
• Serious renal failures (FG < 15) in patients to whom substitutive treatment 
or transplant is contraindicated 
 
h) DEMENTIA (presence of two or more of the following criteria): 
• Severity criteria: unable to dress, wash or eat without assistance 
(GDS/FAST 6c), urinary and faecal incontinence (GDS/FAST 6d-e) or 
unable to communicate meaningfully -≤6 intelligible words- (GDS/FAST 
7)    
• Progression criteria: loss of 2 or more activities of daily living (ADL’s) in 
the last 6 months, despite adequate therapeutic intervention (non-
assessable in hyper-acute situation due to concurrent processes) or 
difficulty swallowing, or denial to eat, in patients who will not receive 
enteral or parenteral nutrition 
• Use of resources criteria: multiple admissions (> 3 in 12 months, due to 
concurrent processes –aspiration pneumonia, pyelonephritis, sepsis, etc.- 
that cause functional and/or cognitive decline)   
 
Socio-demographic data, as gender, age and place of residence were also 
collected. At least one inclusion criteria had to be fulfilled. In case of 
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multimorbidity, with more than one inclusion criteria fulfilled, the most likely 
cause of death for such individual had to be identified by physician and was 
considered the main inclusion criteria. 
All individuals from cohort recruited were assessed by employing the NECPAL 
CCOMS-ICO© tool. Quantitative variables were retrieved, if available, from 
patient’s clinical records by the investigators’ team after interview with healthcare 
professionals (physician and nurse concurrently) to respond to categories 1, 2 and 
indicators to be answered by clinical judgement in category 3. Category 1, the 
surprise question, was answered independently by physician and nurse. 
We categorised recruited individuals as surprise question positive (SQ+) when, at 
least, one of the attending healthcare professionals’ answer was “no” to the 
surprise question (i.e. “I will not be surprised if the patient dies within one year”). 
SQ+ individuals were also considered as NECPAL+ when they presented, at least, 
one positive additional category from among the remaining indicators of the tool, 
as defined (Figure 11). All individuals classified as NECPAL+ were considered 
likely in need of palliative care.  
The individuals’ advanced chronic conditions were categorised according to 
established end of life trajectories, even though individuals with dementia were 





Figure 11. Classification of recruited individuals in three main groups: cohort, SQ+ and NECPAL+. 
 
 
In order to reduce systematic error, all definitions, procedures and measures were 
standardized and followed according to the study operations manual; all people 
involved in collecting data were trained to proceed according to standardized 




Population-based prevalence according to 3 main studied groups (cohort, SQ+, 
NECPAL+ individuals) was calculated based on census data of the County of 
Osona using the population served by the primary care centres as the denominator. 
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The numerator included identified individuals in primary care centres and also 
individuals registered as inpatients at the acute bed hospital, intermediate care 
centre and nursing homes serving these areas at the time of data collection.  
We calculated the specific prevalence within acute bed hospital, intermediate care 
centre and nursing homes separately using as denominator and numerator the total 
number of registered and identified individuals present in each setting, 
respectively, regardless of place of residence. Prevalence per general practitioner 
in primary care was also calculated.  
For global estimates, duplicated cases (individuals identified in more than one 
setting simultaneously) were assigned, by default, to primary care centres. 
Absolute numbers and percentages by age, gender, condition and setting of care 
were calculated for these 3 main groups of individuals. 
Agreement between physicians and nurses in the identification of SQ+ individuals 
was calculated using Kappa statistic. 
The Chi-square test for equality of proportions was used to compare 
characteristics of identified individuals per advanced chronic condition and setting 
of care. The Kruskal-Wallis test was used to compare median age values also per 
advanced chronic condition and setting of care. The results were considered 
significant at p<0.05. 








II. Study II 
Study design  
This is a longitudinal, prospective, cohort study to evaluate the predictive validity 
for mortality at 3, 6, 12 and 24 months of the NECPAL CCOMS-ICO© tool and 
the SQ as screening tools for early palliative care in individuals with advanced 




Based on a chart review, individuals from recruited cohort in previous population-
based prevalence study that died during the 2-year study period were identified. 
To assure comprehensive and accurate mortality data, this information (obtained 
from patient medical records) was cross-checked with lists provided by the 
individual health care services, death registries, and hospital and independent care 
centre registries. Participant mortality status (alive, dead, or lost to follow up) was 
verified at 3, 6, 12 and 24 months and recorded, as well as date, cause, and place 
of death.  
 
 
Statistical analysis  
To evaluate predictive validity for mortality, that is to say, to verify the correlation 
of the two tools (NECPAL and SQ) with individual status at 3 months, 6 months, 
1 year and 2 years, both sensitivity (proportion of true positives -individuals 
deceased and positive identification- among those that did die) and specificity 
(proportion of true negatives -individuals living and negative identification- 
among those that were alive) were assessed, as well as positive predictive value 
(proportion of true positives among those with positive identification) and 
negative predictive value (proportion of true negatives among those with negative 
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identification). The binomial proportion confidence intervals for these measures 
were computed using a normal approximation.  
The Chi-square test for equality of proportions was used to compare mortality 
rates at 3, 6, 12 and 24 months (the Fisher Exact Probability test was used when 
some expected cell frequencies were lower than 5). The results were considered 
significant at p<0.05.  
The nonparametric survival curve estimation was performed using the Kaplan-
Meier method. The Log-rank test was used to determine differences between 
survival curves.   
The risk ratio was calculated to compare risk of death among positive and 
negative identification groups for both tools (NECPAL and SQ) at 3, 6, 12 and 24 
months.  
Variables analysed included advanced chronic condition, setting of care, gender 
and age.  
All statistical analyses were implemented using the SPSS and the R packages. 
 
 
III. Study III 
Study design  
This is a longitudinal, prospective, cohort study to identify factors that are 
associated with mortality within 24 months using the indicators included in the 
NECPAL CCOMS-ICO© tool in individuals with advanced chronic conditions 
identified in a mixed urban-rural district to develop a predictive model for 







Indicators included in the NECPAL CCOMS-ICO© tool and mortality status at 3, 
6, 12 and 24 months were analysed in the whole cohort of individuals recruited in 
previous population-based prevalence study. Collection of information has been 
described previously in studies I and II, respectively. 
 
Statistical analysis  
A semi-parametric Cox proportional regression analysis was used to identify 
indicators included in the NECPAL CCOMS-ICO© tool associated with mortality 
within 24 months after identification.  
Backward and forward step-wise selection of the best predictive covariates was 
carried out by using the AIC (Akaike Information Criterion) statistic. 
Schoenfeld’s residuals test was used to evaluate the proportionality of hazards in 
estimated Cox model. 
The proposed predictive model was used to identify individuals with an increased 
risk to die based on the indicators that were significantly associated with death 
among those included in the NECPAL CCOMS-ICO© tool.  
To evaluate the predictive model’s ability to accurately classify the individuals, 
sensitivity (proportion of individuals predicted to be deceased among those that 
did die) and specificity (proportion of individuals predicted to be alive among 
those that were alive) were calculated. The Receiver Operating Characteristic 
(ROC) curve, a graphical plot of the sensitivity against specificity of the model for 
different cut points, and the area under the curve (AUC) were also calculated. The 
area under the ROC curve is a reflection of how good the estimated model is at 
discriminating between individuals with a risk to die or to be alive. The greater the 
area under the curve the better predictive model. The best possible prediction 
method, also called the perfect classification, should fall at the area in the upper 
left corner (0, 1) of the ROC space representing 100% sensitivity (no false 
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negatives) and 100% specificity (no false positives). An AUC equal to 0.5 suggest 
no discrimination, 0.7 to less than 0.8 being acceptable, 0.8 to 0.9 being excellent, 
and above 0.9 being outstanding discrimination.119 
Predictive model’s ability were additionally studied for estimated Cox models 
proposed per advanced chronic condition and setting of care. 





I. Study I 
A total number of 1.063 individuals were recruited as having advanced chronic 
conditions. Of them, 840 were identified as SQ+. Among these, 783 were also 
identified as NECPAL+ (Figure 12). Only 57 individuals (6.8%) identified as 
SQ+ were not NECPAL+. 
 
          
Figure 12. Recruitment of individuals classified in three main groups: cohort, SQ+ and NECPAL+. 
 
 
Primary care services recruited 68.7% of participant individuals, being the main 
setting of recruitment for all advanced chronic conditions considered, except for 
dementia, where the main setting of recruitment were nursing homes, with 55.9% 
of all recruited individuals suffering from this disease. 38.3% of recruited 
individuals presented advanced frailty and 32.4%, some kind of organ failure 





Table 1. Recruitment per advanced chronic condition and setting of care. 
* Refers to elderly individuals considered to present advanced frailty (subjectively evaluated by 
healthcare professionals, without using specific or standardized measures). 
 
 
Population-based prevalence and prevalence per setting of care 
Population-based prevalence of individuals with advanced chronic conditions who 
may benefit from an early palliative care approach, that is to say NECPAL+ 
individuals, was 1.5% (Table 2).  
Per settings of care, high prevalence were observed in intermediate care centre, 
nursing homes and acute bed hospital, being of 69.6%, 53.9% and 37.3% 
respectively. A prevalence of 1% was observed in primary care centres, with a 




Table 2. Population-based prevalence and prevalence per setting of care of individuals with 
advanced chronic conditions per group (cohort, SQ+ and NECPAL+). 
* Mean population served by each General Practitioner. 




The vast majority of individuals with advanced chronic conditions who may 
benefit from an early palliative care approach were living at home or nursing 
homes. Among NECPAL+ individuals, almost two thirds were female and the 
mean age was 81 years old. SQ+ group and NECPAL+ group were equal among 
individuals with cancer and dementia, as well as among individuals recruited in 
intermediate care centre and acute bed hospital. The most prevalent conditions 
among NECPAL+ individuals were organ failure and advanced frailty, followed 
by dementia. Cancer is the less prevalent disease among individuals with 
advanced chronic conditions who may benefit from an early palliative care 
approach, with a ratio cancer/non-cancer of 1/7 (Table 3).  
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Table 3. Population distribution of recruited individuals (cohort, SQ+ and NECPAL+) per age, 
gender, advanced chronic condition and setting of care. 
 
 
Degree of agreement between physicians and nurses 
There was an agreement of 76.9% of cases between physicians and nurses in the 
identification of SQ+ individuals, which is a moderate degree of concordance 




Table 4. Agreement between physicians and nurses in the identification of SQ+ individuals. 
 
 
Characteristics of recruited individuals  
Only 21% of recruited individuals were not identified as SQ+. 
Among NECPAL+ individuals, choice or demand of palliative care was most 
frequently requested by carers than by individuals itself, with frequencies of 
26.6% and 5.6% respectively. Only 15.5% of NECPAL+ individuals were 
considered to be in need of palliative care approach by healthcare professionals. 
Except for individuals with chronic neurological vascular disease and serious 
chronic renal disease, indicators of severity and progression were present within 
the majority of individuals with diseases for which these specific indicators were 
defined. The groups with high percentages were dementia and cancer, with 
presence of specific severity and progression indicators in 89.1% and 73.6% of 
cases, respectively. 
The most frequent indicators were, nevertheless, those belonging to category 3 
(general clinical indicators of severity and progression) with frequencies reaching 
94.4% among NECPAL+ individuals.  Co-morbidity, identified by Charlson index 
≥2, was present in 71.5% of individuals with advanced chronic conditions and 
palliative care needs (Table 5).  
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Table 5. Characteristics of recruited individuals according to NECPAL CCOMS-ICO© tool 




Significant differences were found regarding age and gender per advanced chronic 
condition.  
Among NECPAL+ individuals, mean age was higher within advanced frailty and 
dementia groups, 86.1 and 85.1 years, respectively; while was lower within organ 
failure and cancer groups, 76.0 and 72.8 years, respectively (Kruskal-Wallis chi-
squared=150.14, p<2.2e-16) (Table 6 and Figure 13). These significant 
differences were equally observed among individuals of SQ+ and cohort groups. 
 
 
Table 6. Age per advanced chronic condition within main groups (cohort, SQ+ and NECPAL+). 
 
Figure 13. Age per advanced chronic condition within NECPAL+ individuals. 
 
Regarding gender, the majority of individuals likely in need of palliative care 
within dementia and advanced frailty groups were female, with frequencies of 
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79.8% and 69.9%, respectively. Male gender was majority within cancer and 
organ failure groups, although with lower frequencies, of 57.4% and 52.6%, 
respectively (chi-square=69.58, p<0.0001) (Table 7). These significant differences 
were equally observed among individuals of SQ+ and cohort groups. 
 
 
Table 7. Gender per advanced chronic condition within main groups (cohort, SQ+ and NECPAL+). 
 
 
Finally, significant differences were found regarding age, gender and advanced 
chronic condition per setting of care.  
Among NECPAL+ individuals, mean age was higher within nursing homes, 85.5 
years, and lower within primary care centres, intermediate care centre and acute 
bed hospital, with 80.3, 78.1 and 76.8 years, respectively (Kruskal-Wallis chi-
squared=34.26, p=1.74e-07) (Table 8 and Figure 14). These significant 




Table 8. Age per setting of care within main groups (cohort, SQ+ and NECPAL+). 
 
Figure 14. Age per setting of care within NECPAL+ individuals. 
 
 
Regarding gender, 81.8% of individuals likely in need of palliative care within 
nursing homes were female, being also majority (58.6%) within primary care 
services. Male gender was majority within acute bed hospital and intermediate 
care centre, although with lower frequencies, of 56.0% and 52.7%, respectively 
(chi-square=39.87, p<0.0001) (Table 9). These significant differences were 




 Table 9. Gender per setting of care within main groups (cohort, SQ+ and NECPAL+). 
 
 
Advanced chronic conditions were distributed significantly different among 
settings of care (Table 10). 69.5% of individuals likely in need of palliative care 
within nursing homes presented dementia, while within acute bed hospital the 
majority group (54.0%) was organ failure followed by cancer (26.0%). The most 
frequent advanced chronic conditions within primary care centres were advanced 
frailty (38.5%) and organ failure (35.4%) while the most frequent ones within 
intermediate care centre were organ failure (38.2%) and cancer (27.3%) (chi-
square=260.50, p<0.0001). These significant differences were equally observed 










II. Study II 
A total of 1063 individuals were followed up for survival. Excluding 4 missing 
cases, data was available to assess 1059 (99.6%) of the initial recruited cohort at 
24 months. Of these, 837 were SQ+ and 780 were NECPAL+ (Figure 15). 
 
 
    
 





Mortality rates per main groups 
At 3, 6, 12 and 24 months, mortality rates within individuals identified as 




 Table 11. Mortality rates at 3, 6, 12 and 24 months within main groups (cohort, SQ+ and 
NECPAL+). 




Significant differences in mortality rates were observed per gender, advanced 
chronic condition and setting of care among NECPAL+ individuals.  
 
Men presented higher mortality rates. At 12 months, the mortality rate for men 
was 38.1% versus 30.5% for women (chi-square=4.72, p=0.030). A higher 
mortality rate at 24 months was 50.3% versus 42.9% (chi-square=4.13, p=0.042). 
These significant differences were equally observed among individuals of SQ+ 
and cohort groups. No significant differences were observed in mortality rates per 






 Table 12. Mortality rates per gender at 3, 6, 12 and 24 months within main groups (cohort, SQ+ and 
NECPAL+). 




Per age, non-significant differences were observed in mortality rates between 
individuals ≤ 75 years and >75 years, neither within any group nor at any time 
point (Table 13).  At 12 months, it was 31.5% versus 34.0%, respectively (chi-
square=0.36, p= 0.551). A higher mortality rate at 24 months was 41.2% versus 







 Table 13. Mortality rates per age at 3, 6, 12 and 24 months within main groups (cohort, SQ+ and 
NECPAL+). 




Significant differences were observed in mortality rates per advanced chronic 
condition among NECPAL+ individuals (Table 14 and Figure 16), with higher 
mortality rates within cancer and dementia individuals, followed by those within 
groups of organ failure and advanced frailty, respectively. At 12 months, mortality 
rates were 64.4% for individuals with cancer, 36.5% in dementia, 30.4% in organ 
failure, and 21.6% in advanced frailty (chi-square=60.47, p<0.0001). At 24 
months, higher mortality rates were 71.3% for individuals with cancer, 56.4% in 
dementia, 42.7% in organ failure, and 30.6% in advanced frailty (chi-
square=58.31, p<0.0001). In most cases (>70%) cause of death was directly 
related to the principal disease or direct complications thereof. These significant 
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differences were equally observed among individuals of SQ+ and cohort groups 
and also at 3 and 6 months within the three main groups. 
 
 
 Table 14. Mortality rates per advanced chronic condition at 3, 6, 12 and 24 months within main 
groups (cohort, SQ+ and NECPAL+). 




Figure 16. Comparison of survival per advanced chronic condition within NECPAL+ individuals 




Finally, significantly different mortality rates were observed among NECPAL+ 
individuals per setting of care (Table 15 and Figure 17), with higher mortality 
rates within individuals recruited in intermediate care centre and acute bed 
hospital, followed by those recruited in nursing homes and primary care centres, 
respectively. At 12 months, mortality rates were 67.3% in intermediate care 
centres, 54.0% in the acute bed hospital, 33.1% in nursing homes, and 28.0% in 
primary care services (chi-square=44.64, p<0.0001). At 24 months, higher 
mortality rates were 70.9% in intermediate care centres, 62.0% in the acute bed 
hospital, 57.8% in nursing homes, and 38.0% in primary care services (chi-
square=40.94, p<0.0001). The most common place of death was the intermediate 
care centre (37.3%), followed by nursing homes (24.1%), home (16.4%), and 
acute care hospital (16.1%). These significant differences were equally observed 
among individuals of SQ+ and cohort groups and also at 3 and 6 months within 




Table 15. Mortality rates per setting of care at 3, 6, 12 and 24 months within main groups (cohort, 
SQ+ and NECPAL+). 




Figure 17. Comparison of survival per setting of care (1=primary care services, 2=intermediate care 







Validity of the NECPAL CCOMS-ICO© tool as screening tool for early 
palliative care from a population-based perspective 
A total of 1059 individuals were available for survival analysis. Of these, 780 
were identified as NECPAL+ and 279 as NECPAL-. Regarding the SQ, 837 were 
identified as SQ+ and 222 as SQ- (Figure 18). 
 
  





At 12 months, the mortality rates for NECPAL+ and NECPAL- individuals 
differed significantly: 33.5% versus 9.0% (chi-square=62.58, p<0.00001). 
Individuals who were identified as NECPAL+ had 3.73 times the risk of death 
compared to patients who were identified as NECPAL- (CI: 2.54-5.50). At 24 
months, higher mortality rates, of 45.8% versus 18.3%, respectively (chi-
square=65.57, p<0.00001) and a lower risk of death, of 2.50, although more 
accurate (CI: 1.93-3.25), were observed (Table 16 and Figure 19). This tendency, 
increasing mortality rates and decreasing risk ratio, improving its accuracy, is 





Table 16. Mortality rates per NECPAL and SQ identification at 3, 6, 12 and 24 months.  




Figure 19. Survival at 24 months: a comparison between NECPAL+ and NECPAL- individuals (Log 
rank test: chi-square 64.717, p-value=0.000). 
 
 
Compared to NECPAL identification, the mortality rates observed for SQ+ and 
SQ- individuals are slightly lower and the risk of death is slightly higher, although 
less accurate, in SQ+ compared to NECPAL+ individuals, a constant tendency 
observed at any analysed time point.  
 
At 12 months, the NECPAL CCOMS-ICO© tool presents very high sensitivity 
(91.3, CI: 87.2-94.2) and very high negative predictive value (NPV) (91.0, CI: 
86.9-94.0), with low specificity (32.9, CI: 29.6-36.3), explained by high number 
of false positives, and low positive predictive value (PPV) (33.5, CI: 30.2-36.9), 
explained by low number of true positives (low mortality rate) and  high number 
of false positives (Table 17).  
 
At 24 months, it improves specificity (35.0, CI: 31.3-38.7) and PPV (45.8, CI: 
42.3-49.3), although they remain low, decreasing sensitivity (87.5, CI: 84.3-90.7) 




A tendency to improve specificity and PPV, maintaining high sensitivity and 
NPV, is consistently observed at consecutive time points analysed (3, 6, 12 and 24 
months). 
 
Compared to NECPAL CCOMS-ICO© tool, SQ presents slightly better sensitivity 





Table 17. Sensitivity, specificity, and predictive values of NECPAL CCOMS-ICO© tool and SQ at 
3, 6, 12 and 24 months (1059 evaluable cases). 
L indicates living; D: deceased.  
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Exploring the validity of the NECPAL CCOMS-ICO© tool as screening tool 
for early palliative care per advanced chronic condition 
Cancer 
A small sample of 108 individuals with cancer were available for survival 
analysis. Of these, 101 were identified as NECPAL+ and 7 as NECPAL-, with the 
same classification among SQ individuals (101 SQ+ and 7 SQ-). 
 
At 12 months, the mortality rates for NECPAL+ and NECPAL- individuals with 
cancer were non-significantly different: 64.4% versus 28.6% (Fisher, p=0.10). 
Individuals who were identified as NECPAL+ had 2.25 times the risk of death 
compared to patients who were identified as NECPAL-. Nevertheless, confidence 
interval encompasses 1 (CI: 0.69-7.33), which suggests no difference in risk of 
death, that is to say that mortality in each group is the same (Table 18).  
 
At 24 months, higher mortality rates and significantly different, of 71.3% versus 
28.6% (Fisher, p=0.031) were observed. NECPAL+ individuals with cancer had 
2.50 times the risk of death compared to patients who were identified as 
NECPAL-. Nevertheless, again confidence interval encompasses 1 (CI: 0.77-
8.10), which suggests no difference o little difference in risk of death between 
groups.  
 
Consistently with these results, survival curves for NECPAL+ and NECPAL- 
individuals (Figure 20) were almost non-significantly different, a comparison 
result which is probably influenced by the small simple size among NECPAL- 
individuals. 
 





Table 18. Mortality rates per NECPAL and SQ identification in cancer at 3, 6, 12 and 24 months. 





Figure 20. Survival at 24 months: a comparison between NECPAL+ and NECPAL- individuals with 




At 12 months, the NECPAL CCOMS-ICO© tool presents very high sensitivity 
(97.0, CI: 88.7-99.5) and acceptable although inaccurate NPV (71.4, CI: 30.3-
94.9), explained by number of false negatives; with acceptable PPV (64.4, CI: 
54.1-73.5), explained by high number of true positives (moderate mortality rate), 
and very low specificity (12.2, CI: 4.6-27.0), explained by high number of false 
positives (Table 19).  
 
This predictive validity improves at 24 months (sensitivity: 97.3, CI: 89.7-99.5; 
NPV: 71.4, CI: 30.3-94.9; specificity: 14.7, CI: 5.5-31.8 and PPV: 71.3, CI: 61.3-
79.6), explained by increase of true positives (increase of mortality rate) although 
specificity remains very low because of high number of false positives. 
 
A tendency to improve slightly specificity and clearly PPV, maintaining high 
sensitivity and acceptable NPV, is consistently observed at consecutive time 




Compared to NECPAL CCOMS-ICO© tool, SQ presents the same results, as 
positive and negative identification were exactly the same for both tools (101 vs 
7). 
 
Table 19. Sensitivity, specificity, and predictive values of NECPAL CCOMS-ICO© tool and SQ in 
cancer at 3, 6, 12 and 24 months (108 evaluable cases). 





A relatively small sample of 202 individuals with dementia were available for 
survival analysis. Of these, 181 were identified as NECPAL+ and 21 as 
NECPAL-. Regarding the SQ, 184 were identified as SQ+ and 18 as SQ-. 
 
At 12 months, the mortality rates for NECPAL+ and NECPAL- individuals with 
dementia were non-significantly different: 36.5% versus 14.3% (chi-square=4.12, 
p=0.074). Individuals who were identified as NECPAL+ had 2.55 times the risk 
of death compared to patients who were identified as NECPAL-. Nevertheless, 
confidence interval encompasses 1 (CI: 0.88-7.41), which suggests no difference 
in risk of death, that is to say that mortality in each group is the same (Table 20).  
 
At 24 months, higher mortality rates although non-significantly different, of 
56.4% versus 38.1% (chi-square=2.53, p=0.112) were observed. The risk of death 
among individuals identified as NECPAL+ was 1.48 times as high as the risk of 
death among individuals identified as NECPAL-. Nevertheless, again confidence 
interval encompasses 1 (CI: 0.84-2.59), which suggests no difference in risk of 
death between groups.  
 
Consistently with these results, survival curves for NECPAL+ and NECPAL- 
individuals (Figure 21) were non-significantly different. 
 
Compared to NECPAL identification, the mortality rates observed for SQ+ and 
SQ- individuals are slightly lower among SQ+ and slightly higher among SQ-; 
and the relative risks of death, and their accuracy, are quite the same at any 
analysed time point.  
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Table 20. Mortality rates per NECPAL and SQ identification in dementia at 3, 6, 12 and 24 months. 






Figure 21. Survival at 24 months: a comparison between NECPAL+ and NECPAL- individuals with 
dementia (Log rank test: chi-square 2.6, p-value=0.11). 
 
 
At 12 months, the NECPAL CCOMS-ICO© tool presents very high sensitivity 
(95.7, CI: 87.0-98.9) and high NPV (85.7, CI: 62.6-96.2), with very low 
specificity (13.5, CI: 8.4-20.8), explained by high number of false positives, and 
low PPV (36.5, CI: 29.5-44.0), explained by low number of true positives (low 
mortality rate) and high number of false positives (Table 21).  
 
This predictive validity changes at 24 months improving PPV (56.4, CI: 48.8-
63.6), explained by an increase of true positives (increase of mortality rate), but 
worsening NPV, included accuracy, (61.9, CI: 38.7-81.0), explained by an 
increase of false negatives; maintaining very high sensitivity (92.7, CI: 85.7-96.6) 
and very low specificity (14.1, CI: 8.0-23.3) 
 
A tendency to improve slightly specificity and PPV, maintaining high sensitivity 
and NPV (except at 24 months), is consistently observed at consecutive time 




Compared to NECPAL CCOMS-ICO© tool, SQ presents slightly worse predictive 
validity at any analysed time point. 
 
 
Table 21. Sensitivity, specificity, and predictive values of NECPAL CCOMS-ICO© tool and SQ in 
dementia at 3, 6, 12 and 24 months (202 evaluable cases). 





A sample of 405 individuals with advanced frailty were available for survival 
analysis. Of these, 245 were identified as NECPAL+ and 160 as NECPAL-. 
Regarding the SQ, 284 were identified as SQ+ and 121 as SQ-. 
 
At 12 months, the mortality rates for NECPAL+ and NECPAL- individuals 
differed significantly: 21.6% versus 8.1% (chi-square=12.95, p=0.0003). 
Individuals who were identified as NECPAL+ had 2.66 times the risk of death 
compared to patients who were identified as NECPAL- (CI: 1.50-4.72) (Table 
22).  
 
At 24 months, higher mortality rates, of 30.6% versus 17.5%, respectively (chi-
square=8.78, p=0.003) and a lower relative risk of death, of 1.75, although more 
accurate (CI: 1.19-2.57), were observed. This tendency, increasing mortality rates 
and decreasing risk ratio, improving its accuracy, is consistently observed at 
consecutive time points analysed (3, 6, 12 and 24 months). 
 
Consistently with these results, survival curves for NECPAL+ and NECPAL- 
individuals (Figure 22) were significantly different. 
 
Compared to NECPAL identification, the mortality rates observed for SQ+ and 
SQ- individuals are slightly lower and the relative risk of death is slightly higher, 
although clearly less accurate, in SQ+ compared to NECPAL+ individuals, a 





Table 22. Mortality rates per NECPAL and SQ identification in advanced frailty at 3, 6, 12 and 24 
months. 






Figure 22. Survival at 24 months: a comparison between NECPAL+ and NECPAL- individuals with 
advanced frailty (Log rank test: chi-square 9.7, p-value=0.00187). 
 
 
At 12 months, the NECPAL CCOMS-ICO© tool presents high sensitivity (80.3, 
CI: 68.3-88.7) and very high NPV (91.9, CI: 86.2-95.4), with low specificity 
(43.4, CI: 38.0-48.8), explained by high number of false positives, and low PPV 
(21.6, CI: 16.8-27.4), explained by very low number of true positives (very low 
mortality rate) and high number of false positives (Table 23).  
 
The predictive validity is worse at 24 months, decreasing sensitivity (72.8, CI: 
63.0-80.9) and NPV (82.5, CI: 75.5-87.9, explained by higher number of false 
negatives, maintaining specificity (43.7, CI: 38.1-49.5) and slightly improving 
PPV (30.6, CI: 25.0-36.9), explained by higher number of true positives (increase 
of mortality rate). 
 
A tendency to improve specificity and PPV, maintaining high sensitivity and NPV 
(except at 24 months), is consistently observed at consecutive time points 




Compared to NECPAL CCOMS-ICO© tool, SQ presents slightly better sensitivity 
and NPV, and slightly worse specificity and PPV at any analysed time point. 
 
 
Table 23. Sensitivity, specificity, and predictive values of NECPAL CCOMS-ICO© tool and SQ in 
advanced frailty at 3, 6, 12 and 24 months (405 evaluable cases). 






A sample of 344 individuals with organ failure were available for survival 
analysis. Of these, 253 were identified as NECPAL+ and 91 as NECPAL-. 
Regarding the SQ, 268 were identified as SQ+ and 76 as SQ-. 
 
At 12 months, the mortality rates for NECPAL+ and NECPAL- individuals 
differed significantly: 30.4% versus 7.7% (chi-square=18.76, p=0.00001). 
Individuals who were identified as NECPAL+ had 3.96 times the risk of death 
compared to patients who were identified as NECPAL- (CI: 1.90-8.26) (Table 
24).  
 
At 24 months, higher mortality rates, of 42.7% versus 14.3%, respectively (chi-
square=23.68, p=0.00001) and a lower relative risk of death, of 2.99, although 
more accurate (CI: 1.77-5.04), were observed. This tendency, increasing mortality 
rates and decreasing risk ratio, improving its accuracy, is not consistently 
observed at consecutive time points analysed (3, 6, 12 and 24 months) due to an 
increasing risk ratio, although inaccurate, at 6 months. 
 
Consistently with these results, survival curves for NECPAL+ and NECPAL- 
individuals (Figure 23) were significantly different. 
 
Compared to NECPAL identification, the mortality rates observed for SQ+ and 
SQ- individuals are slightly lower. The relative risk of death is slightly lower, and 
more accurate, at 3 and 6 months; and higher at 12 and 24 months, although less 
accurate, in SQ+ compared to NECPAL+ individuals. 
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Table 24. Mortality rates per NECPAL and SQ identification in organ failure at 3, 6, 12 and 24 
months. 





Figure 23. Survival at 24 months: a comparison between NECPAL+ and NECPAL- individuals with 
organ failure (Log rank test: chi-square 22.9, p-value=1.7e-06). 
 
 
At 12 months, the NECPAL CCOMS-ICO© tool presents very high sensitivity 
(91.7, CI: 83.0-96.3) and very high NPV (92.3, CI: 84.3-96.6), with low 
specificity (32.3, CI: 26.8-38.4), explained by high number of false positives, and 
low PPV (30.4, CI: 24.9-36.6), explained by very low number of true positives 
(very low mortality rate) and high number of false positives (Table 25).  
 
At 24 months, it improves specificity (35.0, CI: 28.8-41.7), explained by lower 
number of false positives, and PPV (45.8, CI: 42.3-49.3), explained by higher 
number of true positives (increase of mortality rate) and lower number of false 
positives, although both of them remain low; decreasing sensitivity (87.5, CI: 
84.3-90.7) and NPV (81.7, CI: 77.2-86.2), explained by higher number of false 
negatives. 
 
A tendency to improve specificity and PPV, maintaining high sensitivity and 





Compared to NECPAL CCOMS-ICO© tool, SQ presents slightly better sensitivity 
and NPV, and slightly worse specificity and PPV at any analysed time point. 
 
 
Table 25. Sensitivity, specificity, and predictive values of NECPAL CCOMS-ICO© tool and SQ in 
organ failure at 3, 6, 12 and 24 months (344 evaluable cases). 




Exploring validity of the NECPAL CCOMS-ICO© tool as screening tool for 
early palliative care per setting of care 
Primary care centres 
A sample of 727 individuals recruited at primary care centres were available for 
survival analysis. Of these, 521 were identified as NECPAL+ and 206 as 
NECPAL-. Regarding the SQ, 554 were identified as SQ+ and 173 as SQ-. 
 
At 12 months, the mortality rates for NECPAL+ and NECPAL- individuals 
differed significantly: 28.0% versus 7.8% (chi-square=34.98, p<0.00001). 
Individuals who were identified as NECPAL+ had 3.61 times the risk of death 
compared to patients who were identified as NECPAL- (CI: 2.21-5.89) (Table 
26).  
 
At 24 months, higher mortality rates, of 38.0% versus 14.1%, respectively (chi-
square=39.35, p<0.00001) and a lower risk of death, of 2.70, although more 
accurate (CI: 1.89-3.85), were observed. This tendency, increasing mortality rates 
and decreasing risk ratio, improving its accuracy, is consistently observed at 
consecutive time points analysed (3, 6, 12 and 24 months). 
 
Consistently with these results, survival curves for NECPAL+ and NECPAL- 
individuals (Figure 24) were significantly different. 
 
Compared to NECPAL identification, the mortality rates observed for SQ+ and 
SQ- individuals are slightly lower, as well as the risk ratio, lower in SQ+ 
compared to NECPAL+ individuals, a constant tendency observed at any analysed 





Table 26. Mortality rates per NECPAL and SQ identification in primary care centres at 3, 6, 12 and 
24 months. 





Figure 24. Survival at 24 months: a comparison between NECPAL+ and NECPAL- individuals in 
primary care (Log rank test: chi-square 38.2, p-value=6.41e-10). 
 
 
At 12 months, the NECPAL CCOMS-ICO© tool presents very high sensitivity 
(90.1, CI: 84.2-94.1) and very high NPV (92.2, CI: 87.5-95.4), with low 
specificity (33.6, CI: 29.8-37.7), explained by high number of false positives, and 
low PPV (28.0, CI: 24.2-32.1), explained by very low number of true positives 
(very low mortality rate) and high number of false positives (Table 27).  
 
At 24 months, it improves specificity (35.4, CI: 31.2-39.8), explained by lower 
number of false positives, and PPV (38.0, CI: 33.8-42.3), explained by higher 
number of true positives (increase of mortality rate) and lower number of false 
positives, although both of them remain low; decreasing sensitivity (87.2, CI: 
82.0-91.1) and NPV (86.0, CI: 80.2-90.2), explained by higher number of false 
negatives. 
 
A tendency to improve specificity and PPV, maintaining high sensitivity and 





Compared to NECPAL CCOMS-ICO© tool, SQ presents slightly better sensitivity 
and NPV, and slightly worse specificity and PPV at any analysed time point. 
 
 
Table 27. Sensitivity, specificity, and predictive values of NECPAL CCOMS-ICO© tool and SQ in 
primary care centres at 3, 6, 12 and 24 months (727 evaluable cases). 




Intermediate care centre 
A small sample of 74 individuals recruited at intermediate care centre were 
available for survival analysis. Of these, 55 were identified as NECPAL+ and 19 
as NECPAL-, with the same classification among SQ individuals (55 SQ+ and 19 
SQ-). 
 
At 12 months, the mortality rates for NECPAL+ and NECPAL- individuals 
differed significantly: 67.3% versus 15.8% (chi-square=15.07, p=0.0001). 
Individuals who were identified as NECPAL+ had 4.26 times the risk of death 
compared to patients who were identified as NECPAL- (CI: 1.48-12.23) (Table 
28).  
 
At 24 months, higher mortality rates, of 70.9% versus 31.6%, respectively (chi-
square=9.17, p=0.0025) and a lower risk of death, of 2.25, although more accurate 
(CI: 1.13-4.45), were observed. This tendency, increasing mortality rates and 
decreasing risk ratio, improving its accuracy, is consistently observed at 
consecutive time points analysed (12 and 24 months). At 3 and 6 moths, risk ratio 
was not calculable due to the absence of deaths among NECPAL- individuals.  
 
Consistently with these results, survival curves for NECPAL+ and NECPAL- 
individuals (Figure 25) were significantly different. 
 




Table 28. Mortality rates per NECPAL and SQ identification in intermediate care centre at 3, 6, 12 
and 24 months. 






Figure 25. Survival at 24 months: a comparison between NECPAL+ and NECPAL- individuals in 
intermediate care centre (Log rank test: chi-square 11.3, p-value=0.000787). 
 
 
At 12 months, the NECPAL CCOMS-ICO© tool presents very high sensitivity 
(92.5, CI: 78.6-98.0) and high although inaccurate NPV (84.2, CI: 59.5-95.8), 
with low specificity (47.1, CI: 30.2-64.6), explained by high number of false 
positives, and acceptable PPV (67.3, CI: 53.2-79.0), explained by high number of 
true positives (high mortality rate) despite the number of false positives (Table 
29).  
 
At 24 months, it improves PPV (70.9, CI: 56.9-82.0), explained by higher number 
of true positives (slightly increase of mortality rate) and lower number of false 
positives, decreasing sensitivity (86.7, CI: 72.6-94.5) and NPV (68.4, CI: 43.5-
86.5), explained by higher number of false negatives; as well as specificity (44.8, 
CI: 27.0-64.0), explained by lower number of true negatives. 
 
A tendency to improve specificity and PPV, maintaining high sensitivity and 
NPV, is consistently observed at consecutive time points analysed (3, 6 and 12 
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months). Although PPV is higher at 24 months, predictive validity is worse at this 
time point. 
 
Compared to NECPAL CCOMS-ICO© tool, SQ presents the same results, as 
positive and negative identification were exactly the same for both tools (55 vs 
19). 
Table 29. Sensitivity, specificity, and predictive values of NECPAL CCOMS-ICO© tool and SQ in 
intermediate care centre at 3, 6, 12 and 24 months (74 evaluable cases). 
L indicates living; D: deceased. 
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Acute bed hospital 
A small sample of 54 individuals recruited at acute bed hospital were available for 
survival analysis. Of these, 50 were identified as NECPAL+ and 4 as NECPAL-. 
Regarding the SQ, 51 were identified as SQ+ and 3 as SQ-. 
 
At 12 months, the mortality rates for NECPAL+ and NECPAL- individuals were 
non-significantly different: 54.0% versus 0.0% (Fisher, p=0.111). Risk ratio was 
not calculable at any time point due to the absence of deaths among NECPAL- 
individuals. (Table 30).  
 
At 24 months, higher mortality rates for NECPAL+ and NECPAL- individuals 
differed significantly: 62.0% versus 0.0% (Fisher, p=0.028).  
 
Consistently with these results, survival curves for NECPAL+ and NECPAL- 
individuals (Figure 26) were non-significantly different, a comparison result 
which is probably influenced by the small simple size and the lack of deaths 
among NECPAL- individuals. 
 
Compared to NECPAL identification, the mortality rates observed for SQ+ and 
SQ- individuals are slightly lower among SQ+ and the same among SQ- (absence 





Table 30. Mortality rates per NECPAL and SQ identification in acute bed hospital at 3, 6, 12 and 24 
months. 






Figure 26. Survival at 24 months: a comparison between NECPAL+ and NECPAL- individuals in 
acute bed hospital (Log rank test: chi-square 3.8, p-value=0.051). 
 
 
At 12 months, the NECPAL CCOMS-ICO© tool presents perfect sensitivity 
(100.0, CI: 84.5-100.0) and perfect although inaccurate NPV (100.0, CI: 39.6-
100.0), with very low specificity (14.8, CI: 4.9-34.6), explained by high number 
of false positives, and acceptable PPV (54.0, CI: 39.5-67.9), explained by 
considerable number of true positives (moderate mortality rate) although the 
number of false positives (Table 31).  
 
This predictive validity improves at 24 months increasing PPV (62.0, CI: 47.2-
75.0), explained by higher number of true positives (increase of mortality rate) 
and lower number or false positives, and specificity (17.4, CI: 5.7-39.5), explained 
by lower number or false positives; maintaining perfect sensitivity (100.0, CI: 
86.3-100.0) and perfect although inaccurate NPV (100.0, CI: 39.6-100.0). 
 
A tendency to improve slightly specificity and PPV, maintaining perfect 
sensitivity and NPV, is consistently observed at consecutive time points analysed 
(3, 6, 12 and 24 months). 
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Compared to NECPAL CCOMS-ICO© tool, SQ presents slightly worse predictive 
validity at any analysed time point. 
 
Table 31. Sensitivity, specificity, and predictive values of NECPAL CCOMS-ICO© tool and SQ in 
acute bed hospital at 3, 6, 12 and 24 months (54 evaluable cases). 






A relatively small sample of 204 individuals recruited at nursing homes were 
available for survival analysis. Of these, 154 were identified as NECPAL+ and 50 
as NECPAL-. Regarding the SQ, 177 were identified as SQ+ and 27 as SQ-. 
 
At 12 months, the mortality rates for NECPAL+ and NECPAL- individuals 
differed significantly: 33.1% versus 12.0% (chi-square=8.36, p=0.0038). The risk 
of death among individuals identified as NECPAL+ was 2.76 times as high as the 
risk of death among individuals identified as NECPAL- (CI: 1.26-6.04).  
 
At 24 months, higher mortality rates, of 57.8% versus 32.0%, respectively (chi-
square=10.05, p=0.0015) and a lower risk of death, of 1.81, although more 
accurate (CI: 1.18-2.77), were observed (Table 32). This tendency, increasing 
mortality rates and decreasing risk ratio, improving its accuracy, is consistently 
observed at consecutive time points analysed (6, 12 and 24 months), except at 3 
months. 
 
Consistently with these results, survival curves for NECPAL+ and NECPAL- 
individuals (Figure 27) were significantly different. 
 
Compared to NECPAL identification, the mortality rates observed for SQ+ and 
SQ- individuals are slightly lower among SQ+ and clearly lower among SQ-; and 





Table 32. Mortality rates per NECPAL and SQ identification in nursing homes at 3, 6, 12 and 24 
months. 






Figure 27. Survival at 24 months: a comparison between NECPAL+ and NECPAL- individuals in 




At 12 months, the NECPAL CCOMS-ICO© tool presents high sensitivity (89.5, 
CI: 77.8-95.6) and high NPV (88.0, CI: 75.0-95.0), with low specificity (29.9, CI: 
22.8-38.1), explained by high number of false positives, and low PPV (33.1, CI: 
25.9-41.2), explained by low number of true positives (low mortality rate) and 
high number of false positives (Table 33).  
 
At 24 months, it improves specificity (34.3, CI: 25.3-44.6), explained by lower 
number of false positives, and clearly improves PPV (57.8, CI: 49.6-65.6), 
explained by higher number of true positives (increase of mortality rate) and 
lower number of false positives; maintaining sensitivity (84.8, CI: 76.1-90.8) and 
clearly worsening NPV (68.0, CI: 53.2-80.1), explained by higher number of false 
negatives. 
 
A tendency to improve specificity and PPV, maintaining high sensitivity and 
NPV, is consistently observed at consecutive time points analysed (3, 6 and 12 




Compared to NECPAL CCOMS-ICO© tool, SQ presents better sensitivity and 
NPV, included at 24 months, and worse specificity and PPV at any analysed time 
point. 
 
Table 33. Sensitivity, specificity, and predictive values of NECPAL CCOMS-ICO© tool and SQ in 
nursing homes at 3, 6, 12 and 24 months (204 evaluable cases). 




III. Study III 
The Cox model, a regression method for survival data, provides estimates of the 
hazard ratios, and their confidence intervals, of the explanatory variables. The 
hazard ratio is an estimate of the ratio of the hazard rate in the exposed versus the 
unexposed group. The hazard rate is the probability that if the event in question 
has not already occurred, it will occur in the next time interval, divided by the 
length of that interval. The time interval is made very short, so that in effect the 
hazard rate represents an instantaneous rate. 
 
In this study, the hazard ratio indicates the relative risk of death in individuals 
with versus without an identified indicator at any given point in time, since an 
assumption of proportional hazards regression is that the hazard ratio is constant 
over time. This assumption of proportional hazards should always be tested. 
 
For example, a hazard ratio of 2.0 for an identified indicator means that an 
individual presenting such indicator who has not yet died by a certain time has 
twice the chance of being dead at the next point in time compared to someone 
who does not present that indicator. 
 
 
Identifying indicators associated with mortality within 24 months 
A total of 388 individuals died during 2-year follow-up. A total of 1004 
individuals were analysed. 59 observations were missing and, thus, deleted. 
 
In the multivariate Cox model, identification of palliative care needs by healthcare 
professionals [hazard ratio (HR) 2.91, 95% confidence interval (CI) 2.24-3.79], 
infections with systemic impact (HR 2.23, 95% CI 1.50-3.30), and the surprise 
question (HR 2.09, 95% CI 1.45-3.01) were the indicators included in the 
NECPAL CCOMS-ICO© tool associated with a higher risk of mortality (Table 
34). Some other indicators of advanced frailty, as severe dependency (HR 1.87, 
95% CI 1.44-2.43), nutritional decline (HR 1.53, 95% CI 1.23-1.90) or 
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confusional syndrome (HR 1.44, 95% CI 1.11-1.87), were associated with a 
higher risk of mortality within 24 months after identification, as well as 
individual’s request for palliative care approach (HR 1.61, 95% CI 1.01-2.46). 
Co-morbidity (Charlson index, HR 1.12, 95% CI 1.07-1.18) and age (HR 1.02, 
95% CI 1.01-1.03) were also associated with an increased risk of death. 
 
 




Evaluating the proportionality of hazards in predictive model 
The effect of “identification of palliative care needs by healthcare professionals” 
and “nutritional decline” were non proportional, meaning that the hazard ratio of 
these variables is time dependent (Table 35). In such cases, the estimated hazard 
ratio for these two covariates can be understood as ‘average effect’ over observed 
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time points. There was no violation of the proportionality assumption for the rest 
of indicators. 
 




Testing the time dependent covariates is equivalent to testing for a non-zero slope 
in a generalized linear regression of the scaled Schoenfeld residuals on increasing 
transformations of time.  A non-zero slope is an indication of a violation of the 
proportional hazard assumption. Graphical method employing Schoenfeld 
residuals for “identification of palliative care needs by healthcare professionals” 
and “nutritional decline” indicators (Figures 28 and 29) show a decreasing trend 
until 6 months, with no trend over time after this time point. This might lead to the 
conclusion that proportional hazard assumption is violated for both indicators and 






Figure 28. Plot of Schoenfeld residuals against transformed time: analysis of proportional hazard 
assumption verification for “identification of palliative care needs by healthcare professionals”. 
 
  
Figure 29. Plot of Schoenfeld residuals against transformed time: analysis of proportional hazard 




As soon as it is stated that proportional hazard assumption is not satisfied for a 
covariate, and whether this changing impact is considered also of interest, it 
should be decided which approach is to be chosen in terms of Cox model 
construction and modification. There are two methods that are being considered 
most often: a) introducing interactions of selected covariates with function of time 
and b) stratification model.  
 
 
Interaction with time 
The first method uses interactions of the covariates for which proportional hazard 
assumption is not satisfied, “identification of palliative care needs by healthcare 
professionals” and “nutritional decline”, with a time transformation. We 
considered a unit step function with step at 6 months. Including this time 
transformation, we assumed proportional hazard ratios before and after 6 months 
for the two covariates. 
 
The HR in the multivariate modified Cox model for “identification of palliative 
care needs by healthcare professionals” before 6 months increases from 2.91 (95% 
CI 2.24-3.79) in the initial model to 4.78 (95% CI 3.36-6.80) (Table 36). Results 
are quite the opposite after 6 months: the coefficient for “identification of 
palliative care needs by healthcare professionals” is 0.40 [Coef = 1.56 + (-1.16) = 
0.40, SE (coef) = 0.23] and HR [Exp (coef)] is 1.5 (95% CI 0.96-2.35, p value = 
0.078). As HR after 6 months is not statistically significant, the conclusion is that 
“identification of palliative care needs by healthcare professionals” indicator 
increases the risk of death during the first 6 months, but not after this time point. 
In fact, after this time point, it is not a predictor of mortality. 
 
Results are quite similar for “nutritional decline” indicator. Before 6 months, HR 
increases from 1.53 (95% CI 1.23-1.90) in the initial model to 2.00 (95% CI 1.43-
2.79). After 6 months, the coefficient for “nutritional decline” is 0.21 [Coef = 0.69 
+ (-0.48) = 0.21, SE (coef) = 0.15] and HR [Exp (coef)] is 1.24 (95% CI 0.92-
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1.66, p value = 0.159). The conclusion is the same, as HR after 6 months is not 
statistically significant, “nutritional decline” indicator increases the risk of death 
during the first 6 months, but not after this time point. Therefore, after 6 months, 
“nutritional decline” is not a predictor of mortality. 
 
 
Table 36. Multivariate modified Cox model, including interaction between the indicators 
“identification of palliative care needs by healthcare professionals” and “nutritional decline” and the 
unit step function at 6 months.  
 
 
Regarding the rest of indicators associated with a higher risk of death -infections 
with systemic impact, the surprise question, severe dependency, nutritional 
decline, confusional syndrome, individual’s request for palliative care approach, 
co-morbidity and age- there are very discrete differences in the covariate’s 
influence on the hazard level between the initial model and the model adding 
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interactions with time, and HR of each indicator remains practically without 
modifications in the two models.  
 
After adding interactions with time, for “identification of palliative care needs by 
healthcare professionals” and “nutritional decline”, the assumption of proportional 
hazards (statistical significance) is verified again (Table 37). As newly added 
variables turn out to be non-significant, it indicates that proportional hazard 
assumption is satisfied for the given covariates, which means that their effect is 
not changing over time. 
 
 
Table 37. Proportional hazards evaluation in modified model (interactions with time). 
“Identification of palliative care needs by healthcare professionals” indicates before 6 months. 
“Identification of palliative care needs by healthcare professionals_t” indicates after 6 months. 
“Nutritional decline” indicates before 6 months. 





The second method that enables to handle non-proportional hazards is 
stratification. The main idea is to split the whole sample into subgroups on the 
basis of categorical variable which is called stratification variable and re-estimate 
the model, letting the baseline hazard function differ between these subgroups. In 
this case, stratification variables are “identification of palliative care needs by 
healthcare professionals” (present vs absent) and “nutritional decline” (present vs 
absent), resulting in the splitting of the whole sample into 4 subgroups. 
 
It makes sense to choose a categorical covariate as a stratification variable if it 
interacts with time (i.e. proportional hazard assumption is not satisfied for this 
covariate) and is not of primary interest, as stratification of the model 





Table 38. Multivariate modified Cox model, excluding stratification indicators “identification of 
palliative care needs by healthcare professionals” and “nutritional decline” from explanatory 




As it can be noticed, hazard ratios for explanatory indicators do not differ to a 
large extent as compared with those in the initial model not stratified. 
 
The assumption of proportional hazards (statistical significance) is verified again 
(Table 39), indicating that proportional hazard assumption is satisfied for all 





Table 39. Proportional hazards evaluation in stratified model. 
 
 
Evaluating predictive model 
For practical application, the main product of a Cox model is a prognostic 
index. The ROC curve shows the possible combination of sensitivity and 
specificity for predicting the risk of death at different cut-off points of the 
prognostic index. For example, in the initial model, at 3 months a cut-off of 0.31 
implies that individuals with an estimated score above this point were predicted to 
die within 3 months while those with a score equal to or below 0.31 were 
predicted to be alive. This classification successfully predicted 76% of all 
individuals who died (sensitivity) and 76% of all individuals who were alive 
(specificity) (Table 40). 
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To assess the model’s discrimination ability to predict the risk of death at different 








The AUC was progressively decreasing through time, from excellent 
discrimination at 3 and 6 months (0.83 (95% CI 0.79-0.88) and 0.82 (95% CI 
0.79-0.86, respectively) to acceptable discrimination at 12 and 24 months (0.77 
(95% CI 0.74-0.81) and 0.74 (95% CI 0.71-0.77, respectively) (Figure 30). At 3, 6 






Figure 30. Evaluation of the ability to predict death within 3, 6, 12 and 24 months. Results expressed 




Nevertheless, it should be taken into account that hazard ratios for two covariates 
in the model (“identification of palliative care needs by healthcare professionals” 
and “nutritional decline”) were time dependent. Explanation of hazard ratio 
‘average effect’ may probably have affected the model’s discrimination before 
and after 6 months.  
 
It could not be rejected that the variation of the effect through time of these two 
time dependent indicators were related to heterogeneity of studied sample. 
Anyway, stratification model importantly pointed it out. As stratification of the 
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model automatically excluded stratification indicators from explanatory variables 
set and both indicators, “identification of palliative care needs by healthcare 
professionals” and “nutritional decline”, were of primary interest, an alternative 
approach consisting of splitting the whole sample into potentially more 






Exploring identification of factors associated with mortality and development 
of predictive models per condition  
Cancer 
A total of 72 individuals died during 2-year follow-up. A total of 105 individuals 
were analysed. 3 observations were missing and, thus, deleted. 
 
In the multivariate Cox model, identification of palliative care needs by healthcare 
professionals (HR 3.38, 95% CI 1.87-6.11), carer’s request for palliative care 
approach (HR 1.98, 95% CI 1.11-3.55), and severe emotional distress (HR 1.71, 
95% CI 1.01-2.92) were the only indicators included in the NECPAL CCOMS-
ICO© tool associated with a higher risk of mortality among individuals with 
cancer (Table 41).  
 




There was no violation of the proportionality assumption for any of the indicators 
associated with mortality within 24 months in recruited individuals with cancer, 




 Table 42. Proportional hazards evaluation in cancer. 
 
 
The AUC was progressively increasing through time, from acceptable 
discrimination at 3 and 6 months (0.71 (95% CI 0.61-0.82) and 0.78 (95% CI 
0.69-0.87, respectively), with highest concurrent sensitivity and specificity above 
70%, to excellent discrimination at 12 months [0.86 (95% CI 0.79-0.93)] and 
highest concurrent sensitivity and specificity above 80%. At 24 months, the 
model’s discrimination is acceptable [0.80 (95% CI 0.73-0.88)] and highest 









Figure 31. Evaluation of the ability to predict death within 3, 6, 12 and 24 months in cancer. Results 










A total of 110 individuals died during 2-year follow-up. A total of 200 individuals 
were analysed. 4 observations were missing and, thus, deleted. 
 
In the multivariate Cox model, identification of palliative care needs by healthcare 
professionals (HR 2.46, 95% CI 1.46-4.15) and pressure sores GIII-IV (HR 2.34, 
95% CI 1.28-4.29) were the only indicators included in the NECPAL CCOMS-
ICO© tool associated with a higher risk of mortality within 24 months among 
individuals with dementia (Table 44).  
 




There was no violation of the proportionality assumption for any of the indicators 
associated with mortality within 24 months in recruited individuals with dementia, 
meaning that their hazard ratio were constant over time (Table 45). 
 





Nevertheless, the model failed to discriminate between individuals with a risk to 
die or to be alive at any time point analysed, with AUC below 0.60 at 3, 6, 12 and 
24 months (Table 46 and Figure 32). 
 





Figure 32. Evaluation of the ability to predict death within 3, 6, 12 and 24 months in dementia. 









A total of 98 individuals died during 2-year follow-up. A total of 374 individuals 
were analysed. 33 observations were missing and, thus, deleted. 
 
In the multivariate Cox model, infections with systemic impact (HR 4.11, 95% CI 
1.68-10.01), confusional syndrome (HR 2.73, 95% CI 1.71-4.36), identification of 
palliative care needs by healthcare professionals (HR 2.70, 95% CI 1.33-5.52) and 
complex/intense nursing care needs (HR 2.35, 95% CI 1.36-4.06) were the 
indicators included in the NECPAL CCOMS-ICO© tool associated with a higher 
risk of mortality (Table 47). Some other indicators, as falls (HR 1.95, 95% CI 
1.08-3.50), co-morbidity (Charlson index, HR 1.16, 95% CI 1.05-1.27), urgent 
admissions (HR 1.11, 95% CI 1.01-1.23) and age (HR 1.05, 95% CI 1.02-1.09) 
were also associated with an increased risk of death within 24 months after 
identification.  
 
 Table 47. Factors associated with mortality within 24 months in recruited individuals with advanced 





There was no violation of the proportionality assumption for any of the indicators 
associated with mortality within 24 months in recruited individuals with advanced 
frailty, meaning that their hazard ratio were constant over time (Table 48). 
 
 Table 48. Proportional hazards evaluation in advanced frailty. 
 
 
The AUC was progressively decreasing through time, from outstanding 
discrimination at 3 months [0.92 (95% CI 0.85-0.99)], with highest concurrent 
sensitivity and specificity above 80%, to acceptable discrimination at 6, 12 and 24 
months [0.79 (95% CI 0.70-0.87), 0.73 (95% CI 0.65-0.81) and 0.72 (95% CI 
0.66-0.78), respectively] (Table 49 and Figure 33). At 6 and 12 months, highest 
concurrent sensitivity and specificity were above 70%, decreasing below this 








Figure 33. Evaluation of the ability to predict death within 3, 6, 12 and 24 months in advanced 





A total of 109 individuals died during 2-year follow-up. A total of 312 individuals 
were analysed. 32 observations were missing and, thus, deleted. 
 
In the multivariate Cox model, the surprise question (HR 3.07, 95% CI 1.54-6.15), 
infections with systemic impact (HR 2.96, 95% CI 1.66-5.26) and carer’s request 
for palliative care approach  (HR 2.31, 95% CI 1.47-3.61) were the indicators 
included in the NECPAL CCOMS-ICO© tool associated with a higher risk of 
mortality (Table 50). Some other indicators, as falls (HR 1.99, 95% CI 1.03-3.86), 
severe dependency (HR 1.87, 95% CI 1.07-3.27), confusional syndrome (HR 
1.74, 95% CI 1.07-2.83), complex/intense nursing care needs (HR 1.69, 95% CI 
1.08-2.65) and age (HR 1.02, 95% CI 1.003-1.04) were also associated with an 
increased risk of death within 24 months after identification.  
 
This is the only condition where identification of palliative care needs by 
healthcare professionals does not appear as an indicator associated with mortality 
within 24 months, and also the only one where the surprise question does, 




 Table 50. Factors associated with mortality within 24 months in recruited individuals with organ 
failure (n=344 individuals). 
 
 
There was no violation of the proportionality assumption for any of the indicators 
associated with mortality within 24 months in recruited individuals with organ 




 Table 51. Proportional hazards evaluation in organ failure. 
 
 
The AUC was progressively decreasing through time until 12 months, from 
excellent discrimination at 3 months [0.81 (95% CI 0.71-0.91)], with highest 
concurrent sensitivity and specificity around 70%, to acceptable discrimination at 
6 and 12 [0.79 (95% CI 0.70-0.88) and 0.74 (95% CI 0.67-0.81), respectively], 
with a slightly increase in the AUC at 24 months [0.75 (95% CI 0.69-0.80) (Table 
52 and Figure 34). At 6 and 24 months, highest concurrent sensitivity and 
specificity were around 70%. The model’s discrimination ability showed its worse 








Figure 34. Evaluation of the ability to predict death within 3, 6, 12 and 24 months in organ failure. 




A summary of factors associated with mortality within 24 months in recruited 




Table 53. Summary table showing the hazard ratio (HR) of factors associated with mortality within 





Exploring identification of factors associated with mortality and development 
of predictive models per setting of care 
Primary care centres 
A total of 208 individuals died during 2-year follow-up. A total of 667 individuals 
were analysed. 64 observations were missing and, thus, deleted. 
 
In the multivariate Cox model, identification of palliative care needs by healthcare 
professionals (HR 2.97, 95% CI 2.03-4.33) and the surprise question (HR 2.07, 
95% CI 1.33-3.24) were the indicators included in the NECPAL CCOMS-ICO© 
tool associated with a higher risk of mortality within 24 months among 
individuals recruited from primary care centres  (Table 54). Some other indicators, 
as severe dependency (HR 1.83, 95% CI 1.23-2.72), complex/intensive nursing 
care needs (HR 1.68, 95% CI 1.21-2.33), nutritional decline (HR 1.39, 95% CI 
1.02-1.91), urgent admissions (HR 1.27, 95% CI 1.13-1.42), co-morbidity 
(Charlson index, HR 1.10, 95% CI 1.04-1.18) and age (HR 1.03, 95% CI 1.01-






Table 54. Factors associated with mortality within 24 months in individuals recruited from primary 
care centres (n=731 individuals). 
 
 
The effect of “identification of palliative care needs by healthcare professionals” 
was non proportional, meaning that it was a time dependent covariate (Table 55). 
In such case, hazard ratio for this covariate can be understood as ‘average effect’ 
over observed time points. There was no violation of the proportionality 
assumption for the rest of indicators. 
 
Graphical method employing Schoenfeld residuals for “identification of palliative 
care needs by healthcare professionals” indicator (Figure 35) show a decreasing 
trend until approximately 6 months, with no trend over time after this time point. 
This might lead to the conclusion that proportional hazard assumption is violated 









Figure 35. Plot of Schoenfeld residuals against transformed time: analysis of proportional hazard 
assumption verification for “identification of palliative care needs by healthcare professionals” in 






The AUC was progressively decreasing through time, from excellent 
discrimination at 3 and 6 months (0.85 (95% CI 0.78-0.92) and 0.82 (95% CI 
0.76-0.87, respectively) to acceptable discrimination at 12 and 24 months (0.74 
(95% CI 0.70-0.79) and 0.73 (95% CI 0.69-0.77, respectively) (Table 56 and 
Figure 36). For 3 and 6 months, highest concurrent sensitivity and specificity were 
above 70%. At 12 and 24 months, highest concurrent sensitivity and specificity 
slightly decreased and were around 70%.  
 
 Table 56. Model’s discrimination ability in primary care centres.  
 
Nevertheless, model’s discrimination ability should be considered with caution, 
taken into account that hazard ratio for one covariate in the model (“identification 
of palliative care needs by healthcare professionals”) was time dependent. 
Explanation of hazard ratio ‘average effect’ would probably affect the model’s 





Figure 36. Evaluation of the ability to predict death within 3, 6, 12 and 24 months in primary care 
centres. Results expressed by the receiver operating characteristic (ROC) curve.  
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Intermediate care centre 
A total of 40 individuals died during 2-year follow-up. A total of 69 individuals 
were analysed. 5 observations were missing and, thus, deleted. 
 
In the multivariate Cox model, individual’s request for palliative care approach 
(HR 8.79, 95% CI 3.49-22.11), nutritional decline (HR 4.02, 95% CI 2.03-7.93), 
functional decline (HR 2.67, 95% CI 1.32-5.41) and co-morbidity (Charlson 
index, HR 1.13, 95% CI 1.02-1.25) were the only indicators included in the 
NECPAL CCOMS-ICO© tool associated with a higher risk of mortality within 24 
months among individuals recruited from intermediate care centre (Table 57).  
 
 Table 57. Factors associated with mortality within 24 months in individuals recruited from 
intermediate care centre (n=74 individuals). 
 
 
The effect of “nutritional decline” was non proportional, meaning that it was a 
time dependent covariate (Table 58) and hazard ratio for this covariate should be 
understood as ‘average effect’ over observed time points. There was no violation 






 Table 58. Proportional hazards evaluation in intermediate care centre. 
 
 
Graphical method employing Schoenfeld residuals for “nutritional decline” 
indicator (Figure 37) show a decreasing trend over time. This might lead to the 
conclusion that proportional hazard assumption is violated for this indicator and 
its effect might be changing over time. 
 
Figure 37. Plot of Schoenfeld residuals against transformed time: analysis of proportional hazard 






At any observed time point, the model’s discrimination is excellent [0.90 (95% CI 
0.83-0.97) at 3 months, 0.90 (95% CI 0.83-0.98) at 6 months, 0.90 (95% CI 0.83-
0.97) at 12 months and 0.89 (95% CI 0.82-0.96) at 24 months] (Table 59 and 
Figure 38). At 3 and 6 months, highest concurrent sensitivity and specificity were 
above 80%. At 12 and 24 months, highest concurrent sensitivity and specificity 
slightly decreased and were around 80%.  
 
 Table 59. Model’s discrimination ability in intermediate care centre.  
 
Nevertheless, model’s discrimination ability should be considered with caution, 
taken into account that hazard ratio for one covariate in the model (“nutritional 
decline”) was time dependent. Explanation of hazard ratio ‘average effect’ would 





Figure 38. Evaluation of the ability to predict death within 3, 6, 12 and 24 months in intermediate 







Acute bed hospital  
A total of 30 individuals died during 2-year follow-up. A total of 53 individuals 
were analysed. 1 observation was missing and, thus, deleted. 
 
In the multivariate Cox model, pressure sores GIII-IV (HR 21.17, 95% CI 2.24-
199.67), severe dependency (HR 11.23, 95% CI 2.02-62.44),  nutritional decline 
(HR 4.25, 95% CI 1.90-9.53), male gender (HR 2.78, 95% CI 1.22-6.30) and 
functional decline (HR 2.86, 95% CI 1.28-6.41) were the indicators included in 
the NECPAL CCOMS-ICO© tool associated with a higher risk of mortality within 
24 months among individuals recruited from acute bed hospital (Table 60).  
 
 Table 60. Factors associated with mortality within 24 months in individuals recruited from acute 
bed hospital (n=54 individuals).  
 
 
The effect of “functional decline” was non proportional, meaning that it was a 
time dependent covariate (Table 61) and hazard ratio for this covariate should be 
understood as ‘average effect’ over observed time points. There was no violation 





 Table 61. Proportional hazards evaluation in acute bed hospital. 
 
 
Graphical method employing Schoenfeld residuals for “functional decline” 
indicator (Figure 39) show an increasing trend over time. This might lead to the 
conclusion that proportional hazard assumption is violated for this indicator and 
its effect might be changing over time. 
 
Figure 39. Plot of Schoenfeld residuals against transformed time: analysis of proportional hazard 






At any observed time point, the model’s discrimination is excellent [0.82 (95% CI 
0.70-0.95) at 3 months, 0.87 (95% CI 0.77-0.97) at 6 months, 0.88 (95% CI 0.79-
0.96) at 12 months and 0.84 (95% CI 0.74-0.94) at 24 months] (Table 62 and 
Figure 40). At 3 and 6 months, highest concurrent sensitivity and specificity were 
around 80%. At 12 and 24 months, highest concurrent sensitivity and specificity 
slightly decreased and were around 70%.  
 
 Table 62. Model’s discrimination ability in acute bed hospital.  
 
Nevertheless, model’s discrimination ability should be considered with caution, 
taken into account that hazard ratio for one covariate in the model (“functional 
decline”) was time dependent. Explanation of hazard ratio ‘average effect’ would 





Figure 40. Evaluation of the ability to predict death within 3, 6, 12 and 24 months in acute bed 










A total of 106 individuals died during 2-year follow-up. A total of 201 individuals 
were analysed. 3 observations were missing and, thus, deleted. 
 
In the multivariate Cox model, identification of palliative care needs by healthcare 
professionals (HR 17.65, 95% CI 7.07-44.04), the surprise question (HR 3.48, 
95% CI 1.41-8.62) and pressure sores GIII-IV (HR 2.73, 95% CI 1.35-5.53) were 
the indicators included in the NECPAL CCOMS-ICO© tool associated with a 
higher risk of mortality within 24 months among individuals recruited from 
nursing homes (Table 63). Some other indicators, as confusional syndrome (HR 
1.80, 95% CI 1.03-3.12) and age (HR 1.03, 95% CI 1.01-1.06) were associated 
with a higher risk of mortality within 24 months after identification. It is 
remarkable the effect of complexe/intensive nursing care needs, as its presence 
was associated with a lower risk of mortality within 24 months among individuals 
recruited from nursing homes (HR 0.21, 95% CI 0.06-0.76). 
 
 Table 63. Factors associated with mortality within 24 months in individuals recruited from nursing 





There was no violation of the proportionality assumption for any of the indicators 
associated with mortality within 24 months in individuals recruited from nursing 
homes, meaning that their hazard ratio were constant over time (Table 64). 
 
 Table 64. Proportional hazards evaluation in nursing homes. 
 
 
Nevertheless, the model was poor discriminating between individuals with a risk 
to die or to be alive at 3, 6 and 12 months, with AUC below 0.70 (Table 65 and 
Figure 41). Only at 24 months the AUC showed acceptable discrimination, 









Figure 41. Evaluation of the ability to predict death within 3, 6, 12 and 24 months in nursing homes. 





A summary of factors associated with mortality within 24 months in recruited 




Table 66. Summary table showing the hazard ratio (HR) of factors associated with mortality within 





IX. General discussion 
The overall aim of this thesis was to evaluate the usefulness of the NECPAL 
CCOMS-ICO© tool in identifying individuals with advanced chronic conditions 
who may benefit from an early palliative care approach, through employing it as a 
tool to determine the population-based prevalence of these individuals (Study I), 
evaluating its predictive validity for mortality at 3, 6, 12 and 24 months to inform 
usefulness as screening tool for early palliative care (Study II) and identifying the 
indicators that were associated with mortality within 24 months to develop a 




The population-based prevalence of individuals with advanced chronic conditions 
who may benefit from an early palliative care approach has been determined for 
the first time in a district, together with their characteristics and setting of care, 
employing one of the existing available tools to identify those individuals who 
may require such care: the NECPAL CCOMS-ICO© tool.  
 
This prospective approach constitutes an innovative assessment of the population-
based needs for palliative care. Methodologies based on retrospective assessments 
from causes of death, can also provide valid estimates.104 105 106 107 108 109 110 111 
Nevertheless, they are not useful for improving clinical practice, as they do not 
allow to identify patients in clinical settings, while this innovative approach is 
potentially transferable to the clinical practice and allows prospective 
identification. 
 
NECPAL+ individuals are mainly among the elderly population. They live at 
home and nursing homes, although high prevalence is observed in intermediate 
care centre and acute bed hospital. Organ failure and advanced frailty are the most 
155 
 
common conditions they present, followed by dementia and cancer. There are 
higher proportions of women and non-cancer patients. These findings are 
consistent with previous published estimations.120 94 Physicians and nurses 
identify different groups of individuals with advanced chronic conditions who 
may benefit from an early palliative care approach. 
 
The groups of individuals identified as SQ+ and NECPAL+ are nested groups and 
they are, essentially, the same population. Differences between these groups are 
attributable to differences observed among individuals with organ failure and 
advanced frailty conditions, as well as among individuals recruited in primary 
care centres and nursing homes. These findings would point out the higher 
severity presented by individuals identified as NECPAL+ with dementia and 
cancer, confirmed by the highest frequencies of disease-specific indicators of 
severity and progression presented by individuals with these two conditions, and 
also among those identified in acute bed hospital and intermediate care centre, 
consistently reflecting the kind of population, more seriously ill, expected to be 
attended to in these settings of care. 
 
As almost all SQ+ individuals presented, at least, one additional NECPAL 
CCOMS-ICO© tool’s positive indicator, an additional interpretation based on 
these findings would suggest that scant differences exist between SQ+ 
identification and NECPAL+ identification, as currently defined, and that it does 
not improve the performance of the SQ in identifying patients likely in need of 
palliative care. Thus, according to this evidence, it would be questionable the 
recommendation of its use. 
 
In the same way, almost all identified individuals with advanced chronic 
conditions who may benefit from an early palliative care approach, regardless of 
condition, presented some positive general clinical indicator of severity and 
progression from category 3 of the NECPAL CCOMS-ICO© tool. This suggests 
the importance of these kind of indicators and of this innovative approach, based 
on the accumulation of deficits to define severe advanced frailty, to identify this 
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population.121 122 Other available tools, such as PIG90 and SPICT,21 are mainly 
based on Fried criteria123 and, thus, designed to identify moderate frailty at an 
early stage (shrinking, weakness, poor endurance, slowness, and low activity). In 
the NECPAL CCOMS-ICO© tool, four of six domains within this high prevalent 
category correspond to deficits caused by severe advanced frailty, encompassing 
geriatric syndromes (with increasing evidence as an independent prognostic 
marker),124 use of resources and nutritional and functional decline, both 
considered as dynamic as well as static variables. These general clinical indicators 
of severity and progression are not usually registered in mortality registries, which 
usually record individual diseases. This innovative approach jointly with high 
proportion of elderly people in studied County would explain high prevalence 
found. 
 
Moreover, a broad majority of NECPAL+ individuals presented co-morbidities, 
making clear that multimorbidity is the most common condition among the elderly 
people.14 125 The majority presence of general clinical indicators of severity and 
progression, regardless of condition, among identified individuals with advanced 
chronic conditions who may benefit from an early palliative care approach would 
suggest that disease-specific approach in an exclusive way may not be the most 
suitable one to identify this population.  
 
Only in one-quarter of identified individuals, a request for palliative care approach 
or limitations to the use of major therapeutic interventions was made by 
individuals’ carer. The frequency of requests made by individuals themselves is 
quite lower, which highlights the paternalistic pattern within the Spanish cultural 
context.126 
 
One of the most significant findings from this study is the lack of concordance 
between physicians and nurses regarding the identification of individuals likely in 
need of palliative care. There was a moderate degree of agreement, with different 
populations being identified as SQ+, showing differences in their prediction of 
mortality before 12 months among recruited individuals. This low level of 
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concurrence between medical and nursing staff is consistent with available 
evidence.127 128 Consensus of definition and standardised validated criteria for the 
identification of individuals in need of palliative care are needed and could 
contribute to improve concordance between physicians and nurses. 
 
Additionally, medical and nursing staff judged that a minority of the individuals 
they expected to die within 12 months was in need of a palliative care approach, 
suggesting that this needed approach might be related to recognition by healthcare 
professionals of transition 2 and indication of traditional palliative care more than 
to recognition of transition 1 and indication of early palliative care.129 These 
findings would emphasize the need to reinforce the spreading of conceptual 
transitions in palliative care, systematically screen for palliative care needs in all 
target sub-populations and the importance of a multi-disciplinary approach. 
 
Individual’s characteristics per condition and setting of care show that older 
women with advanced frailty and dementia are often based in home and nursing 
homes, while younger individuals suffering from organ failure and cancer are 
majority in acute bed hospital and intermediate care centre, as could be expected, 
which might be related to their current needs, the presence (or not) of primary 
carers, and required resources for their care. Nevertheless, it is important to point 
out that most identified individuals with advanced chronic conditions who may 
benefit from an early palliative care approach are community-dwelling people, 
except individuals with dementia, mainly based in nursing homes.  
 
The consistent and systematic use of the NECPAL CCOMS-ICO© tool across all 
participating clinical settings showed that identification of these individuals is 







Predictive validity as screening tool 
Among the existing available tools to identify individuals with advanced chronic 
conditions who may benefit from an early palliative care approach, the NECPAL 
CCOMS-ICO© tool has been the first one to be evaluated to determine its 
predictive validity for mortality to inform usefulness as screening tool for early 
palliative care from a population-based perspective. 
 
The NECPAL CCOMS-ICO© tool and the SQ may be used, with a reasonable 
degree of accuracy, to screen individuals for early palliative care to ameliorate 
end-of-life suffering related to advanced chronic conditions. They present high 
sensitivity and high NPV at 3, 6, 12 and 24 months, an important finding given 
the consequences of failing to identify this vulnerable and often undetected and 
under-treated population. From a pragmatic approach, these screening tools 
provide early identification of patients that present a higher risk of death, thus 
enabling early assessment and delivery of early palliative care in individuals who 
screen positive and, effectively, present unmet palliative care needs. 
 
Without screening, palliative care intervention would occur, if happened, 
throughout transition 2. However, end of life begins long before death becomes 
impending, and there is a period at which transition 1 might be detected by a 
screening tool. It is expected that recognition of transition 1 would lead to earlier 
palliative care intervention and that this, in turn, would lead to better outcomes. 
Although, this evidence is not yet available. 
 
According to characteristics that a good screening test should present, the 
NECPAL CCOMS-ICO© tool is inexpensive, easy to administer, cause minimal 
(none) discomfort and is valid, as it distinguishes between individuals who will 
die and will not die. Significantly different mortality rates between NECPAL+ 
and NECPAL- populations and increased risk of death for those with positive 
identification would partially prove this validity. 
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Nevertheless, construct validity of the tool has been just partially explored by 
comparisons of mortality rates and calculation of risk ratios. Additional analysis 
regarding construct validity, such as internal consistency (which would assess the 
consistency of results across the items of the tool for addressing a unified 
construct) and reliability, the last characteristic that a good screening test should 
present (consistency in results with repeated measures, particularly inter-observer 
and intra-observer variability), remain unexplored and further research will be 
needed to better evaluate construct validity of the tool. 
 
The criterion validity of the NECPAL CCOMS-ICO© tool has been explored by 
evaluating its predictive validity. The validity of the NECPAL CCOMS-ICO© tool 
as screening test is based, precisely, on its predictive validity for mortality, that is 
to say on its accuracy in identifying individuals who will die and will not die. 
Predictive validity can only be determined if the accuracy of the screening test can 
be compared to some "gold standard" that establishes the true status. In this study 
the gold standard is death, determined by following the participating individuals 
for a period of 24 months to determine which of them ultimately died. If the 
NECPAL CCOMS-ICO© tool were an ideal screening test, it would be 
exquisitely sensitive (high probability of detecting individuals who will die) and 
extremely specific (high probability that those that will not die will screen 
negative). But this is not the case.  
 
The NECPAL CCOMS-ICO© tool presents high sensitivity, which is extremely 
convenient for screening purposes, but low specificity at 3, 6, 12 and 24 months. 
The probability of the NECPAL CCOMS-ICO© tool correctly identifying 
individuals who will not die was lower than 35% at any time point, that is to say 
there is a high proportion of false positives, individuals who test positive even 
though they really will not die, never lower than 65%, a consequence to screening 
that should need to be properly addressed.130 As some of the individuals identified 
will end up living for years in a fragile state, although some others will die soon, 
all typically need the services that are priorities in the last part of life: advance 
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care planning, comfort measures, assistance for daily activities, family support, 
and so forth.81  
 
NECPAL+ identification relies on the SQ, an estimation of mortality made by 
healthcare professionals and, as far as is known, human prediction on its own is 
fraught with bias.49 Overestimation of survival has been reported when clinicians 
have been asked to predict it.45 In the same way, an overestimation of mortality is 
observed when they are asked to predict it, as SQ does, a circumstance which 
could explain high proportion of false positives identified. Additionally, scant 
differences exist between SQ+ population and NECPAL+ population, as 93% of 
SQ+ individuals were also NECPAL+ individuals. This is the reason that would 
explain why predictive validity of the SQ is practically equal to predictive validity 
that has been calculated for the NECPAL CCOMS-ICO© tool. In light on this 
results, and as has been seen when identifying patients likely in need of palliative 
care with the SQ, the recommendation of its use would be questionable. 
Consequently, criterion of positivity should be reviewed to improve the predictive 
validity for mortality of the NECPAL CCOMS-ICO© tool.131 
 
There are other aspects of predictive validity for mortality that should also be 
considered: the negative and positive predictive values. In this study, NPV is the 
probability that individuals with a negative screening test ultimately don’t die, and 
PPV is the probability that individuals with a positive screening test ultimately 
die. One factor that influences the feasibility or the success of a screening 
program is the yield, i.e., the number of cases detected. It can be estimated from 
the PPV. Sensitivity and specificity are characteristics of the test and are only 
influenced by the test characteristics and the criterion of positivity that is selected. 
In contrast, the positive predictive value of a test, or the yield, is very dependent 
on the prevalence of the disease in the population being tested, in this case, on the 
mortality. The higher mortality is in the population being screened, the higher the 




The NECPAL CCOMS-ICO© tool presents high NPV, which is extremely 
convenient for screening purposes, but low PPV, or yield. Cases detected at 12 
and 24 months were lower than 34% and 46%, respectively. The primary means 
of increasing the yield of a screening program should be to target the tool to 
groups of people who are at higher risk of death. Identifying individuals at high 
risk of death is, therefore, required. 
 
Despite the high proportion of false-positives and the low incidence of mortality, 
the NECPAL CCOMS-ICO© tool presents a sensitivity good enough to correctly 
discriminate nearly all individuals who will die at 3, 6, 12 and 24 months and a 
NPV sufficiently high to correctly predict nearly all the individuals who will live. 
Both predictive values are important for a screening tool intended to identify such 
a vulnerable and often undetected and under-treated population.  
 
Tests can be used in combination to improve either sensitivity or specificity, but at 
the cost of the other, depending on how a positive outcome for the combination of 
tests is defined. This principle was initially used to detect cervical cancer by a Pap 
smear, which had a high sensitivity but a low specificity. As a result, a Pap smear 
detected nearly all cervical cancers but a high proportion of false positives. By 
requiring a sequence of positive Pap smears before taking further diagnostic 
action, however, it was possible to improve specificity of the smear (that is, 
reduce the false positives) without compromising the already high sensitivity 
much.132 Subsequent work led to an improvement on the approach of repeated 
smears, and a single cervical smear can be simultaneously tested for the DNA of 
human papillomavirus, another risk factor for cervical cancer, to improve the 
specificity of a single screen rather than having to rely on repeat Pap testing.133 
 
These strategies, repeated testing and simultaneous testing, may be suggested to 
improve the specificity of the NECPAL CCOMS-ICO© tool, or the SQ as long as 




The predictive validity for mortality of the NECPAL CCOMS-ICO© tool per 
condition and setting of care deserves specific interpretation.  
 
PPV is higher in cancer, followed by dementia and organ failure and, finally, 
advanced frailty. This finding is unsurprising given the different mortality within 
these different conditions. It should be emphasized that advanced frailty was 
assessed by subjective clinical judgment without specific or standardized 
measures. The diagnostic criteria for advanced frailty are much wider,134 135 136 
which could explain greater variability in identification and low mortality within 
this condition, especially in primary care centres. 
 
NPV is lower within conditions of cancer and, especially, dementia. This finding 
is explained by high proportions of false negatives among this groups. 
Furthermore, non-significantly differences in mortality rates between NECPAL+ 
and NECPAL- populations (only at 24 months in individuals with cancer) and no 
difference in risk of death for those with positive and negative identification 
would suggest that validity of the NECPAL CCOMS-ICO© tool within this 
conditions would be worse than validity within conditions of organ failure and 
advanced frailty, probably explained by a sample bias related to a less 
heterogeneous and a more seriously ill population. Higher incidence of mortality 
and highest frequencies of disease-specific indicators of severity and progression 
presented by individuals with these two conditions would support this 
interpretation. Smaller samples sizes could also be influencing these results. 
 
Despite this variability among conditions, as sensitivity and NPV are high, the 
NECPAL CCOMS-ICO© tool and the SQ may be used, with a reasonable degree 
of accuracy, to screen for early palliative care in individuals with cancer,137 138 
dementia, advanced frailty and organ failure131 as a first test that would be 




PPV is higher in intermediate care centre and acute bed hospital, followed by 
nursing homes. Given that patients admitted to such centres—which focus on 
palliative care, rehabilitation, and nursing care, often in older patients or those 
with terminal illnesses—typically suffer from more serious conditions than 
patients at primary care centres, mortality is expected to be higher. This findings 
are also unsurprising as PPV depends on mortality, pointing out a better yield of 
the screening tool in these settings of care compared to primary care centres. 
Nevertheless, the absolute number of cases detected is higher in primary care 
centres than in the other settings of care taken as a whole, an important issue from 
a public health perspective. 
 
Lowest specificity is observed in acute bed hospital. Non-significantly differences 
in mortality rates between NECPAL+ and NECPAL- populations (only at 24 
months) are observed, with the highest proportion of false positives. Nevertheless, 
sensitivity and NPV are the highest possible. Although the small studied sample 
could be influencing these results, they highlight the crucial importance of proper 
management of false positives to accept the suitability of screening.  
 
As sensitivity and NPV are high in all setting of care, the NECPAL CCOMS-
ICO© tool and the SQ may be used, with a reasonable degree of accuracy, to 
screen for early palliative care in primary care centres,94 intermediate care centres, 
acute bed hospitals139 and nursing homes93 as a first test that would be confirmed 
over time by repeated testing or simultaneous testing. 
 
Predictive validity of the NECPAL CCOMS-ICO© tool has been evaluated to 
predict mortality. Nevertheless, a person centred approach based not on diagnosis 
or prognosis, but on the needs of patients underpins pragmatic approach for 
identifying individuals who may benefit from an early palliative care intervention. 
Therefore, predictive validity of available tools to identify these population could 






The NECPAL CCOMS-ICO© tool has been the first existing available tool to 
identify individuals with advanced chronic conditions who may benefit from an 
early palliative care approach that has been employed to develop a predictive 
model for identifying individuals at high risk of death. 
 
A relatively small number of indicators from the NECPAL CCOMS-ICO© tool, 
easily obtained from available records or from healthcare professionals, have been 
proven to be associated with mortality within 24 months. The predictive model 
developed for identifying ‘high risk’ individuals which relies on these predictors 
of mortality - identification of palliative care needs by healthcare professionals, 
infections with systemic impact, the surprise question, severe dependency, 
individual’s request for palliative care approach, nutritional decline, confusional 
syndrome, co-morbidity and age- shows excellent discrimination at 3 and 6 
months and acceptable discrimination at 12 and 24 months, with good sensitivity 
and specificity. 
 
The indicators associated with mortality within 24 months among those included 
in the NECPAL CCOMS-ICO© tool vary according to advanced chronic condition 
–cancer, dementia, advanced frailty and organ failure- and according to setting of 
care –primary care centres, intermediate care centre, acute bed hospital and 
nursing homes-. The simple predictive models developed for identifying ‘high 
risk’ individuals per condition show outstanding and excellent discrimination at 3 
months in advanced frailty and organ failure, respectively, and excellent 
discrimination at 12 months in cancer, with good sensitivity and specificity in all 
cases. Regarding predictive models developed per setting of care, excellent 
discrimination is shown at all studied time points in intermediate care centre and 
acute bed hospital, as well as at 3 and 6 months in primary care centres, all of 




In light of these results, end of life trajectories might turn out to be an excellent 
conceptual framework for the development of predictive models.  
 
The identification of palliative care needs by healthcare professionals is the 
indicator included in the NECPAL CCOMS-ICO© tool which is associated with a 
higher risk of death, followed by the surprise question, which already showed its 
predictive validity as screening tool for early palliative care. Although process of 
judgement and clinicians’ estimates have been reported to be biased,49 these 
results highlight, however, that the ability of physicians to predict outcome is a 
valuable and logical standard on which to base the prospective evaluation of a 
prediction rule141 142 and, even more, the advantage to combine the clinician’s 
predictions, influenced by unquantifiable random variables which influence the 
patients survival, as an additional covariate together with objective prognostic 
factors in a statistical model in order to improve prediction, 143 144 as has been done 
in the developed predictive model.  
 
Among the nine indicators included in the NECPAL CCOMS-ICO© tool 
associated with a higher risk of mortality within 24 months after identification,  4 
indicators were of severe advanced frailty -infections with systemic impact, severe 
dependency, nutritional decline and confusional syndrome-. This results are 
consistent with available evidence, as solid death predictive variables that have 
been proven to be reliable indicators of end of life situation.145 146 147 148 Co-
morbidity (Charlson index) and age are also associated with a higher risk of 
mortality within 24 months. 
 
Frail elderly people have a higher risk of disability compared to non-frail elderly 
people.149 150 151 Persistent or progressive disability has been associated with a 
higher risk of dying in older people, especially when functional ability declines 
rapidly.152 The risk of disability increases with age and there is a significant 
association between disability and morbidity and mortality.153 
Although frailty seems to be a distinct geriatric concept, it also overlaps with 
morbidity and disability.154 Study results and available evidence would support 
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recommendation that severe advanced frailty and, thus, substantial disability 
should be considered for palliative care for control of symptoms, care planning, 
and increased support with personal care needs.155  
 
Individual’s request for palliative care approach is also predictive of death, 
highlighting the extremely valuable information that individuals do provide and 
strengthening underlying reasons for a person centred approach to make clinical 
decisions predicated on the attainment of individuals’ goals of care.112 
 
These findings guarantee the content validation of the NECPAL CCOMS-ICO© 
tool which, compared with similar existing tools,90 21 91 93 94 95 is strengthened by 
containing indicators of severe advanced frailty, disability and request of the 
patient for palliative approach as a triggers to identify individuals likely in need of 
palliative care and as reliable indicators of end of life situation, the value of which 
has been proven. 
 
When modelling a Cox proportional hazard model, a key assumption is 
proportional hazards, that is to say, hazard ratios are constant over time. 
Evaluation of the proportional hazards assumption is essential since its violation 
raises questions regarding the validity of Cox model results which, if 
unrecognized, could result in the publication of erroneous scientific findings.156  
 
In this study, the hazard ratio, that is to say, the relative risk of death within 24 
months in individuals presenting versus not presenting some of the identified 
predictive indicators, is constant over time for all of them except for two 
predictors -“identification of palliative care needs by healthcare professionals” 
and “nutritional decline”-, that have been shown to predict mortality only within 6 
months. After this time point they do not predict mortality in the population-based 
studied sample. 
 
There are various opinions on the importance of the proportional hazards 
assumption with regard to the parameters interpretation. Some authors state that 
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violation from it is nothing extremely problematic as, in such cases, parameter for 
a covariate for which assumption is not satisfied can be understood as ‘average 
effect’ over time points that are observed in a dataset.157 The others, however, 
underline the importance of this assumption and suggest potential modification of 
the model if hazard ratio turns out not to be constant over time for some 
covariates.158 In such cases, it would be worth taking this fact into account and 
estimate the model adjusting for potentially time varying effect of covariate for 
which assumption is not satisfied rather than stating that parameter estimate for 
this covariate expresses its ‘average effect’ on the hazard level. 
 
It is hard to define a general rule for non-proportional hazards handling, as one of 
the three available possibilities (i.e. keeping all covariates in the model and 
neglecting the fact of the violation from non-proportional hazard assumption, 
introducing interaction with time and estimation of stratification model) can be 
taken into consideration. It is also hard to compare these models, especially 
stratification model with non-stratified models, as they differ in their construction. 
The latter approach enables to obtain parameter estimate for covariate for which 
proportional hazard assumption is violated, as well as analyse how hazard ratio 
changes over time, which is impossible if stratification model is chosen. The 
choice of the method needs to be adjusted for the particular situation.159 
 
To handle non-proportional hazards in this study, the three available possibilities 
have been considered. Model’s discrimination ability has been estimated keeping 
all covariates in the model and neglecting the fact of the violation from non-
proportional hazard assumption, assuming the expression of ‘average effect’ on 
the hazard level for “identification of palliative care needs by healthcare 
professionals” and “nutritional decline”. However, introducing interaction with 
time and estimation of stratification model have also been considered, providing 
helpful inputs to understand the underlying explanation of behaviour of these 
death predictive indicators. The variation of their effect through time was 
probably related to heterogeneity of studied sample, as stratification model 
importantly pointed it out.  
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The development of predictive models for identifying individuals at high risk of 
death per condition, that is to say, per end of life trajectory,34 35 36 37 allowed to split 
the whole sample into potentially more homogeneous subgroups which revealed, 
on one hand, the identification of different indicators associated with mortality 
within 24 months according to end of life trajectory and, on the other hand, the 
development of more simple predictive models with proportional hazards for all 
identified predictive indicators. 
 
In dementia, although identification of palliative care needs by healthcare 
professionals and pressure sores GIII-IV have been identified as predictors of 
mortality within 24 months, any good predictive model could be developed. 
Almost 90% of recruited patients presented disease-specific indicators of severity 
and progression, becoming the most seriously ill group recruited.  
 
When distribution of disability trajectories in the last year of life has been 
evaluated according to the conditions leading to death, a predominant trajectory of 
persistently severe disability has been reported only for subjects who die from 
advanced dementia.37 Thus, this probable sample bias, which reflects the pattern 
of persistent severe disability typical of advanced dementia, and which has been 
identified as predictor of mortality,160 could explain the impossibility of 
developing a predictive model which would be able to discriminate between 
individuals with a risk to die or to be alive essentially because it is based on 
indicators related to severe advanced frailty and disability, already present in 
almost all recruited individuals. In light of these results, the predictable pattern of 
persistent severe disability typical of advanced dementia should also be 
considered for palliative care for control of symptoms, care planning, and 
increased support with personal care needs.155  
 
In cancer, and despite a probable sample bias -recruited population not much 
heterogeneous and seriously ill -, some indicators associated with mortality within 
24 months among those included in the NECPAL CCOMS-ICO© tool have been 
identified -identification of palliative care needs by healthcare professionals, 
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carer’s request for palliative care approach and severe emotional distress-. These 
findings would strengthen evidence regarding patient related factors, such as 
performance status, symptoms and laboratory parameters, as more predictive of 
imminent death from cancer than are tumour related factors such as grade, stage, 
or genetic signatures.161 The absence of indicators related to severe advanced 
frailty among those identified as predictors of mortality could be explained by the 
pattern of decline at the end of life typical of cancer, with disability and functional 
decline appearing quite late in the course of the illness34 35 36 and, thus, still not 
present when individuals were recruited or by a probable sample bias with a 
recruited population already presenting frailty.37 Further research is needed. 
 
Individuals who were identified as in need of palliative care by healthcare 
professionals had more than 3 times the risk of death compared to individuals not 
identified. This relevant hazard ratio and the fact that the highest model’s 
discrimination -excellent- is observed at 12 months, exactly the time point 
explored by the surprise question, would evidence the more predictable nature of 
monophasic and easier to anticipate pattern of decline typical of cancer.43 44  
 
Additional indicators included in the developed predictive model for cancer were 
carer’s request for palliative care approach and severe emotional distress. The 
NECPAL CCOMS-ICO© tool is the only such tool, compared with similar 
existing ones,90 21 91 93 94 95 which integrated emotional distress and the request of 
the carer for palliative approach as a triggers to identify individuals likely in need 
of palliative care. These findings strengthen, again, its content validity.  
 
Advanced frailty is the most common condition among recruited population, 
mainly recruited in primary care services. It has been assessed by subjective 
clinical judgment without specific or standardized measures, which has probably 
lead in greater variability in recruitment and, consequently, in a more 




Except identification of palliative care needs by healthcare professionals, all 
indicators associated with mortality within 24 months in this condition are, as 
could be expected, deficits caused by severe advanced frailty, specifically with 
geriatric syndromes -infections with systemic impact, confusional syndrome and 
falls- and use of resources -complex/intense nursing care needs and urgent 
admissions-. Co-morbidity (Charlson index) and age are also associated with a 
higher risk of mortality. Heterogeneous sample and appropriate indicators,145 148 
162 163 152 153 154 would explain the development of an outstanding predictive model 
at 3 months, as well as acceptable predictive models at 6, 12 and 24 months. 
 
Frequent emergency department users appear to experience higher mortality and 
hospital admissions compared with non-frequent users.163 Disability is an adverse 
outcome of frailty that places a high burden on frail individuals, care professionals 
and health care systems.164 Most decedents have high levels of disability in the 
last month of life, yet more than half are not disabled 12 months before death.  
Around 60% of subjects who die from frailty present progressive, catastrophic or 
accelerated disability in the last year of life (only 25% present severe disability 
during the entire year) suggesting that frailty, and subsequently disability, mainly 
appear and worsen during this period of time.37 This evidence is consistent with 
study findings and the possibility of a predictable death in the end of life 
trajectory of frailty. 
 
Although frailty and dementia share illness trajectory of functional decline at the 
end of life,34 35 36 according to available evidence regarding severe advanced frailty 
indicators and pattern of disability 12 months before death, and even predictive 
validity for mortality of the NECPAL CCOMS-ICO© tool in these conditions, it 
would be justified to consider frailty and dementia as two different groups for 
analysis and two different end of life trajectories, as has been done throughout 
studies I, II and III. 
  
Organ failure is the second most common condition among recruited population, 
and has been mainly recruited in primary care centres. Disease-specific indicators 
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of severity and progression have not been analysed to identify indicators 
associated with mortality within 24 months on account of small samples of 
individuals in some diseases but also assuming that older adults are more likely to 
have more than one chronic disease.14 59 
 
Regarding indicators associated with mortality within 24 months, geriatrics 
syndromes predicting death are exactly the same as in advanced frailty -infections 
with systemic impact, falls and confusional syndrome- and, additionally, severe 
dependency. Complex/intense nursing care needs and age, are also associated with 
a higher risk of mortality, as in advanced frailty. The only two indicators that are 
death predictors in advanced frailty and are not in organ failure are co-morbidity 
(Charlson index) and urgent admissions, a relevant fact which would suggest that 
both co-morbidity and, especially, urgent admissions are equally frequents among 
individuals who will die or will be alive. 
 
Carer’s request for palliative care approach, as shown in cancer, is a death 
predictor in organ failure. This result importantly point out the relevance and 
valuable information that carers can provide regarding prognosis in severely 
affected individuals with these long illness trajectories. 
 
Organ failure is the only condition where the surprise question is a predictor of 
mortality within 24 months. In fact, it is the best death predictor within this 
condition. The availability of information provided by disease-specific indicators 
of severity and progression, probably contributing to improve estimations and 
clinical judgement, could explain this result. Nevertheless, organ failure is the 
only end of life trajectory where the identification of palliative care needs by 
healthcare professionals is not a predictor of mortality, demonstrating the lack of 
palliative assessment and integration of palliative care into medical specialties.165 
166 167 
 
It is remarkable, however, that 8 predictive indicators,145 162 148 146 153 easily 
obtained from available records or from healthcare professionals, have made 
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possible the development of an excellent predictive model at 3 months, as well as 
acceptable predictive models at 6, 12 and 24 months. 
Unfortunately, the evaluation of the proportional hazards assumption in predictive 
models developed per setting of care, although presenting excellent discrimination 
at all time point studied in intermediate care centre and acute bed hospital, as well 
as at 3 and 6 months in primary care centres, identifies some indicators for which 
the effect is non proportional, meaning that they are time dependent covariates. 
The variation of their effect through time is again, probably, related to 
heterogeneity of studied sample in each setting of care, as seen with general 
predictive model.  
 
Only in nursing homes, the hazard ratios for all indicators in the developed 
predictive model are constant over time. Nevertheless, poor model’s 
discrimination between individuals with a risk to die or to be alive could be 
explained by main condition suffered by residents in nursing homes, that is, 
dementia, for which any good predictive model could be developed.  
 
As none of available possibilities to handle non-proportional hazards has resulted 
satisfactory or better than to split the whole sample into more homogeneous 
groups to develop predictive models per end of life trajectory, no further analysis 
have been considered in settings of care, taking into account small sample sizes in 
intermediate care centre and acute bed hospital. More research, with sample sizes 
large enough to allow the development of predictive models per end of life 
trajectory in each setting of care would be needed. 
 
 
Strengths and limitations 
The strengths of these studies include the field-assessments on large samples of 
individuals prospectively assessed and identified in different settings of care 
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(community, hospitals and residential homes) to be sure to collect all possible 
cases of patients likely in need of palliative care. 
 
The recruitment was carried out with 100% of participation from both healthcare 
professionals and settings of care that needed to be involved, a common case 
identification methodology followed in all settings and a high level of 
commitment from all participants. 
 
The studies have some limitations. Due to non-probabilistic sampling applied, it is 
not possible to determine representativeness of the study population-based 
sample. Recruitment was conducted in a relatively small district that may not be 
truly representative of the region as a whole. However, the primary care centres 
were randomly selected, and represent 32.9% of the entire County’s population.  
 
Recruitment may have also been affected by ageing population and strong 
influence of geriatric care in the area, as well as by length of the study window.  
 
Availability of quantitative data in clinical charts may have affected description of 
patients’ characteristics and predictive indicators identified. 
 
Another potential limitation is the risk of selection bias, as inclusion criteria were 
based on clinical judgment, which is inherently subjective and can vary depending 
on the setting of care or the healthcare professional. To minimize this bias, all 
definitions, procedures, and measures were standardised and adhered to in 
accordance with the study operations manual.  
 
As this study was based on health professionals’ assessment and routine data, 
patients’ perspective was not included. 
 
For certain conditions and settings of care, a relatively limited number of patients 




Some predictive models seem to have some ability in identifying the population of 
interest, indicating good internal validity. These results are optimistic by 
definition as they derive from the best model that fits the data. The external 
validity is unknown and, thus, the predictive ability of these models should be 







The most relevant contribution of this study to the body of knowledge of palliative 
care consist in the innovative assessment of the population-based needs for 
palliative care through identifying prospectively the population-based prevalence 
of individuals with advanced chronic conditions who may benefit from an early 
palliative care approach using the NECPAL CCOMS-ICO© tool. 
 
Methodologies based on retrospective assessments from causes of death, can also 
provide valid estimates. Nevertheless, they are not useful for improving clinical 
practice, as they do not allow to identify patients in clinical settings, while this 
innovative approach is potentially transferable to the clinical practice and allows 
prospective identification. 
 
There is a clear dissonance between the focus on cancer of most specialist 
palliative care resources and the prevalence of individuals who may benefit from 
an early palliative care approach. A significant shift in thinking is required on how 
health systems identify and manage individuals with advanced chronic conditions, 
mainly community-dwelling and nursing-based people suffering from advanced 
frailty, organ failure and dementia. 
 
General clinical indicators of severity and progression are present in almost all 
identified individuals who may benefit from an early palliative care approach, 
regardless of suffered advanced chronic condition, highlighting the importance of 
these kind of indicators and of such innovative approach, based on the 
accumulation of deficits to define severe advanced frailty, to identify this 
population. 
 
Scant performance differences exist between SQ+ identification and NECPAL+ 
identification, as currently defined, (SQ+ and, at least, one positive additional 
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indicator). Consequently, both tools, NECPAL CCOMS-ICO© and SQ, may be 
equally employed to identify individuals with advanced chronic conditions who 
may benefit from an early palliative care approach, although the NECPAL 
CCOMS-ICO© tool allows the completion of systematic multi-dimensional 
assessments, which makes it more recommendable than using the SQ exclusively. 
 
The consistent and systematic use of the NECPAL CCOMS-ICO© tool across all 
participating clinical settings shows that identification of individuals with 
advanced chronic conditions who may benefit from an early palliative care 
approach is feasible and can be performed in any setting of care in daily clinical 




The NECPAL CCOMS-ICO© tool may be used, with a reasonable degree of 
accuracy, to screen individuals for early palliative care. It presents high sensitivity 
and high NPV, an important finding given the consequences of failing to identify 
this vulnerable and often undetected and under-treated population.  
 
Scant differences in predictive validity for mortality exist between SQ+ 
identification and NECPAL+ identification, as currently defined, (SQ+ and, at 
least, one positive additional indicator). Consequently, both tools, NECPAL 
CCOMS-ICO© and SQ, may be equally employed to screen individuals for early 
palliative care.  
 
There is an overestimation of mortality and, accordingly, a high proportion of 
false positives identified, individuals who test positive even though they really 
will not die. As some of the individuals identified will end up living for years in a 
fragile state, although some others will die soon, all typically need the services 
that are priorities in the last part of life: advance care planning, comfort measures, 
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assistance for daily activities, family support, and so forth. This required 
arrangement of care and services is of crucial importance to accept the suitability 
of screening. 
 
The NECPAL CCOMS-ICO© tool and the SQ provide early identification of 
individuals that present a higher risk of death, thus enabling early assessment and 
delivery of early palliative care in individuals who screen positive and, 
effectively, present unmet palliative care needs. Further additional assessments 
are, then, recommended. 
 
The predictive validity for mortality of the NECPAL CCOMS-ICO© tool and the 
SQ per condition and setting of care show PPV, and yield, according to expected 
mortality. Per condition, higher in cancer and dementia, followed by organ failure 
and, finally, advanced frailty, but with quite similar absolute number of cases 
detected in each group; per setting of care, higher in intermediate care centre, 
acute bed hospital and nursing homes and, finally, primary care centres, but with 
absolute number of cases detected in primary care centres higher than in the other 
settings of care taken as a whole. This is an important issue from a public health 
perspective, making advisable to screen individuals for early palliative care 
regardless of advanced chronic condition and in all settings of care. 
 
Sensitivity and NPV are acceptably high in all conditions and settings of care, 
which would justify to screen individuals for early palliative care using the 





A relatively small number of indicators from the NECPAL CCOMS-ICO© tool, 
easily obtained from available records or from healthcare professionals, have been 
proven to be associated with mortality within 24 months and useful to develop 
simple predictive models for identifying individuals at high risk of death. 
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The NECPAL CCOMS-ICO© tool is essentially based on indicators related to 
severe advanced frailty and disability, and strengthened by containing 
psychological domain as well as request of individual and family for palliative 
approach as a triggers to identify individuals in need of palliative care. All of them 
have been proven to be predictors of mortality and useful to develop simple 
predictive models, which would prove its content validity. 
 
The indicators associated with mortality within 24 months among those included 
in the NECPAL CCOMS-ICO© tool vary according to advanced chronic condition 
and according to setting of care, making clear the heterogeneity of the study 
population-based sample, heterogeneity equally seen among settings of care, and 
explaining the difficulties to develop simple predictive models. 
 
End of life trajectories, a criterion to split the study population-based sample into 
potentially more homogeneous subgroups, may turn out to be an excellent 
conceptual framework for the development of simple predictive models, 
particularly in advanced frailty and organ failure, the most prevalent population-
based advanced chronic conditions, where indicators of severe advanced frailty, 
and subsequently disability, mainly appear and worsen throughout 12 months 
before death. The simple and promising predictive models that have been 
developed should be externally validated. 
 
The indicators included in the NECPAL CCOMS-ICO© tool that have been 
proven to be associated with mortality within 24 months could be useful to review 
the current criterion of positivity of the tool which could lead, potentially, to a 
better identification of ‘high risk’ individuals and, consequently, to an 
improvement of specificity and PPV, and yield. This potential improvement of the 
predictive validity for mortality of the NECPAL CCOMS-ICO© tool to be 







The NECPAL CCOMS-ICO© tool can be considered useful in identifying 
individuals with advanced chronic conditions who may benefit from an early 
palliative care approach.  
 
It can be employed to assess the population-based needs for palliative care 
through identifying prospectively the population-based prevalence of this 
population, an innovative approach which can be potentially useful for improving 
clinical practice. 
 
It can be used, as well as the SQ, as screening tools for early palliative care. It can 
be employed as a first assessment to identify this population, preferably 
accompanied by repeated or additional tests, aiming to improve specificity. 
 
Finally, some of the indicators included in the NECPAL CCOMS-ICO© tool have 
been proven to be associated with mortality within 24 months, which would prove 
its content validity. From a population-based perspective, end of life trajectories 
may turn out to be an excellent conceptual framework for the development of 
simple predictive models for identifying individuals at high risk of death, 
particularly in advanced frailty and organ failure, the most prevalent population-
based advanced chronic conditions, for which simple and promising predictive 









XI. Considerations for further 
research 
Population-based prevalence needs to be confirmed by similar studies in different 
and equivalent demographic areas and settings of care. 
 
Construct validity of NECPAL CCOMS-ICO© tool has been just partially 
explored. Additional analysis, such as internal consistency and reliability remain 
unexplored. 
 
Evidence is needed regarding the expected improvement of the predictive validity 
for mortality of the NECPAL CCOMS-ICO© tool, specifically specificity and 
PPV, whether criterion of positivity is reviewed according to predictors of 
mortality per end of life trajectories. 
 
In the same way, evidence is needed regarding the expected improvement of the 
predictive validity for mortality of the NECPAL CCOMS-ICO© tool, specifically 
specificity and PPV, whether repeated testing and simultaneous testing are 
implemented. 
 
Predictive validity of the NECPAL CCOMS-ICO© tool has been evaluated to 
predict mortality. Nevertheless, it could also be evaluated to predict unmet 
palliative care needs. 
 
Trials need to be conducted to determine whether the effect of implementing 
screening for early palliative care using the NECPAL CCOMS-ICO© tool lead to 
earlier palliative care intervention and this, in turn, lead to better outcomes. 
 
More research, with sample sizes large enough to allow the development of 




Developed simple predictive models per end of life trajectory need to be 
externally validated and large prospective trials need to be conducted to prove the 
predictive models’ ability to identify individuals who are at high risk of death to 
better target early palliative care interventions to reduce suffering and improve 
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